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Abstract for MMed Chemical pathology Dissertation 
George F van der Watt 
Division of Chemical Pathology, Red Cross Childrens' Hospital, National Health 
Laboratory Service and University of Cape Town  
Whole Blood Mitochondrial DNA Depletion in Human Immunodeficiency-virus 
Infected Children 
Background: Nucleoside reverse transcriptase inhibitors (NRTIs) interfere with 
mitochondrial DNA polymerase gamma causing significant toxic effects, including fatal 
lactic acidosis. Little is known about mitochondrial DNA (mtDNA) in human 
immunodeficiency virus (HIV) infected children who face a lifetime exposure to these 
agents. We performed a cross sectional observation of mtDNA levels in whole blood in a 
pediatric population to ascertain the relationship between mtDNA, NRTI regimens and 
parameters of HIV-infection severity. 
Methods: Whole blood mt:nDNA ratios were determined by real-time PCR in three  
groups: 27 presumed HIV-negative, 89 HIV-infected, NRTI-treated and 62 HIV-infected 
treatment-naive children. Multivariate analysis was used to identify variables 
independently associated with mtDNA depletion. 
Results: Mean mt:nDNA ratios were  lower (P < 0.001) at 77% of control in the HIV-
infected antiretroviral treatment (ART) naïve group and 73% of control in the ART 
group,  but not different between the two HIV-infected groups. Mt:nDNA ratios were 
negatively associated with age (P = 0.029), HIV status (P < 0.0001) and Log10 of the 
HIV-1 viral load (P = 0.035) and positively associated with CD4 % (p = 0.032). A 
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stavudine vs zidovudine based regimen was associated with lower but not significant 
levels of mtDNA (P = 0.1). 
Conclusions: Depletion of whole blood mtDNA in children is associated independently 
with HIV-infection and markers of HIV infection severity, and does not improve with 
either stavudine or zidovudine based ART despite virological control, suggesting that 
these agents also deplete mtDNA.  
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attendance of the meeting. 
2006: George van der Watt presented this work at the annual research day of the School 
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oral presentation by a MMed student.  
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PART A 
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Research Protocol for the Project Titled 
Mitochondrial:Nuclear DNA Ratios in Peripheral Blood Leukocytes and Lactate in 
Human Immunodeficiency-virus Infected Children on Antiretroviral Drug 
Regimens 
Submitted September 2004 
Note: This is the original title of the proposal submitted for ethics approval and funding. 
Subsequent to the initiation of the study, the title was appropriately changed to that listed 
as the title on the title page and part C, the manuscript. Notably peripheral blood 
leukocytes were changed to whole blood. 
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reverse-transcriptase inhibitor (NRTI) toxicity in human immunodeficiency virus (HIV) 
infected children, at the HIV Clinic, Red Cross War Memorial Childrens’ Hospital, Cape 
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7. Project
Aim, Objectives and Background 
Aim 
To determine the distribution of peripheral blood leukocyte mitochondrial:nuclear DNA 
(mt:nDNA) ratios and venous lactate in paediatric HIV-infected patients prior to and after 
6 – 12 months of treatment with various ARV regimens in comparison to controls. 
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Objectives 
• To measure mitochondrial:nuclear DNA (mtDNA:nDNA) ratios in peripheral
blood leukocytes (PBLs), and lactate in children with HIV, in comparison to age
matched controls.
• To ascertain the effect of HIV infection itself on mt:nDNA ratios in children.
To ascertain the influence of different HAART regimens on mt:nDNA ratios in
children who have received uninterrupted Antiretroviral (ARV) treatment for 6 -
12  months.
• To determine the correlation between serum lactate levels and mt:nDNA ratios in
the abovementioned groups.
• To provide information that will ultimately lead to developing awareness of, and
a diagnostic and preventative approach to NRTI induced mitochondrial toxicity
in children on ARVs in South Africa.
Background 
The use of potent antiretroviral drugs in combination regimens, now referred to as highly 
active antiretroviral treatment (HAART), has markedly decreased disease progression 
and mortality rates in HIV-infected patients. NRTIs form the backbone of most currently 
used ARV regimens used in the treatment of HIV infection (1).  Most regimens consist of 
two NRTIs and either a protease inhibitor (PI) or a non-nucleoside reverse-transcriptase 
inhibitor (NNRTI). Patients remain on these drug regimens for life, and viral drug 
resistance and drug toxicity remain problematic (2). Important side effects of HAART in 
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children are the lipodystrophy syndrome and mitochondrial toxicity (3-5). Decreased 
bone mineral density and growth retardation are also described (6). 
 Toxicity of the NRTIs is disadvantageous in the long-term management of viral infection 
(7). As a group, NRTIs interfere with mitochondrial DNA polymerase gamma, the key 
enzyme responsible for mitochondrial DNA replication (3,5,8). Stavudine, in particular, 
has repeatedly been associated with a higher incidence of mitochondrial toxicity than 
other commonly used NRTIs (9-13). The clinical manifestations of mitochondrial toxicity 
include: fatigue, weight loss, dyspnoea, nausea and vomiting, abdominal pain, peripheral 
neuropathy, myopathy, cardiomyopathy, Fanconi syndrome, pancreatitis, hepatic 
steatosis and death (9,14). Biochemically, mitochondrial dysfunction can present as 
hyperlactatemia, compensated lactic acidosis or, rarely, as acute decompensated lactic 
acidosis with a high mortality (4,10). 
In South Africa, availability of ARVs is limited. Many children qualifying for HAART 
are critically ill and clinical differentiation of NRTI-induced mitochondrial toxicity from 
HIV-related disease is difficult (Pers comm, B Eley, 2004). Random venous lactate 
measurements have been suggested as a screening tool for NRTI toxicity in adults and 
children (11,15,16). Accurate lactate measurements are difficult to obtain in children due 
to the wide physiological variability associated with physical exertion. Lactate also has a 
poor specificity for NRTI-induced toxicity (17). Tissue hypoxia, due to various HIV 
related disease processes is a notable cause of elevated lactate levels. 
Un
ive
rsi
ty 
Of
 C
ap
e T
ow
n 
 14 
More recently, investigators have identified measurement of the mitochondrial to nuclear 
DNA ratio in leukocytes, using various real-time PCR techniques as a direct and more 
specific marker of NRTI-induced mitochondrial toxicity (10,12,13,15,18,19). These 
studies have demonstrated a decrease in mitochondrial DNA copy number with NRTI use 
in adults (10,12,15,18), and an increase in copy number if the NRTI was withdrawn or 
changed to less toxic NRTIs such as lamivudine. Furthermore, a correlation between low 
mtDNA copy numbers and symptomatic hyperlactatemia has been demonstrated (10,15). 
In adults, mtDNA copy numbers decline by a factor of 0.83 log within six months of 
HAART (13). Furthermore, mean lactate levels have been shown to increase in the first 
six months of HAART, followed by a plateau without significant change for 3 years (20). 
  
Children are particularly vulnerable to the adverse effects of therapy due to a potentially 
longer exposure to HAART and because they are growing actively. HIV infection 
progresses more rapidly in children, and antiretroviral therapy is indicated at an earlier 
stage than in infected adults. The current Western Cape guidelines recommend that all 
children with World Health Organisation (WHO) stage II (moderate) and stage III 
(severe) clinical disease, irrespective of CD4 count, and every child with a CD4 
percentage < 20% (if under 12 months or age) or < 15% (if ≥ 12 months of age) should 
receive antiretroviral therapy. These guidelines are in accordance with the recently 
revised WHO recommendations on antiretroviral therapy in resource-constrained settings 
(1). Between 70% and 85% of all HIV-infected children managed at Red Cross 
Childrens' Hospital currently qualify for treatment. Of the 500 - 600 children requiring 
treatment, some 200 are currently receiving HAART at the Infectious Diseases Clinic. An 
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estimated 30-50% have severe disease or advanced immunosuppression. Whether 
children in the South African setting, with advanced clinical and / or immunological 
disease are more susceptible to drug toxicity is not known. 
 HIV infection itself has a marked effect of inducing a measure of mitochondrial 
dysfunction (21), and asymptomatic, HIV-infected, ARV-naïve adults have  significantly 
lower mtDNA levels than healthy controls (1,13,22). This decrease is greater than that 
associated with NRTI treatment. Whether the degree of virus induced mitochondrial 
depletion prior to the onset of treatment influences the risk for mitochondrial toxicity due 
to NRTIs, remains to be determined. This is a particularly relevant question in South 
Africa where a large percentage of children who are fortunate enough to receive ARVs 
have advanced clinical disease. 
By describing the distribution of a prospective marker for HIV/ARV related 
mitochondrial dysfunction in HIV-infected children, we hope to define the relationship 
between HIV infection and mt:nDNA ratios in children and the effect of NRTI treatment 
on these ratios in a paediatric population.  
Detailed methodology 
Study Population: Patients 
Blood samples will be obtained from two separate populations of HIV infected children. 
The first population will consist of ARV naïve, HIV-infected patients. The second 
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population will consist of children who have completed 6 – 12 months of uninterrupted 
HAART and are enrolled in the existing ARV treatment programme operational at the 
Paediatric HIV Clinic, Red Cross War Memorial Childrens' Hospital. The two 
populations will be age matched. Written informed consent will be obtained from the 
legal parents or guardians through an interpreter/councillor in the clinic. Apart from the 
once off requirement of approximately 0.5ml of blood from each patient, this study will 
make no additional change to any given patients’ routine management as prescribed by 
the infectious disease consultant. Blood will only be obtained for the study when routine 
management phlebotomy is performed. Acquisition of samples will continue until at least 
100 patient samples have been collected in each group. Drug compliance will be 
indirectly ascertained as evidenced by adherence to scheduled clinic follow up visits, 
appropriate return of empty drug containers and response to treatment as determined by 
measurement of viral-load and CD4 count. Based on current experiences, approximately 
90% of patients are expected to be black, Xhosa speaking children residing in the greater 
Cape Town area of the Western Cape and + 10% of enrolled patients are expected to 
default on follow up visits or drug compliance and + 10% are expected to die within the 
first six months of HAART (Pers comm, B Eley, 2004). Death in this period is reported 
to be primarily due to secondary infections or from complications related to immune 
reconstitution. 
 
Additional data that will be accessed from each patient’s routine management 
information will include the following: demographic data, Centres for Disease Control 
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and WHO clinical grading, specific HAART drug regimen prescribed, and routine blood 
work, which will include viral-loads and CD4 counts.  
 
At present (2004) the preferred first-line regimens for children treated at Red Cross 
Childrens’ Hospital are: Stavudine (or zidovudine) plus lamivudine plus ritonavir for 
children < 10 kg or < 3 years old, or stavudine (or zidovudine) plus lamivudine plus 
efavirenz for children > 10 kg or > 3 years of age. Lopinavir / ritonavir co-formulation is 
used as an alternative to ritonavir or efavirenz in children > 6 months old. Zidovudine is 
used if patients do not have access to refrigerated storage required for the stavudine 
suspension. 
 
Study Population: Controls 
A control population of age matched children will be used to establish a normal control 
group for measurement of PBL mt:nDNA ratios. These children will be sourced from 
patients within the Division of Paediatric Surgery at Red Cross Hospital who are 
undergoing elective day surgery for minor procedures. Blood will be obtained from 
patients who are judged to be clinically free of systemic disease or treatment, that may 
influence mitochondrial DNA levels or their determination by Real-Time PCR. A 200µl 
aliquot of EDTA whole blood will only be taken from these children if full prior parental 
informed consent has been obtained at least 6 hours prior to the elective procedure. In 
theses cases, parental informed consent will be obtained by the principal investigator. If 
consent is obtained, the aliquot of blood will only be taken from those children who 
require an intravenous (I.V) line for the surgical procedure as judged by the attending 
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anaesthetist. The sample will be collected on placement of the I.V line only. No child will 
be subjected to a second phlebotomy if sample volumes obtained are inadequate for the 
purpose of this study. Most I.V lines in this setting are placed after gas induction of light 
anaesthesia by the attending anaesthetist. In the event of any relative contraindication e.g. 
time constraints or anaesthetic complications no sample will be taken from that individual 
patient. To remain within accepted ethical guidelines no child will be tested for HIV 
infection, nor will any information related to the HIV status of the child, his / her siblings 
or the mother be elucidated from the child, parent, guardian or caregiver at any stage. 
Information in regard to prior HIV testing of any of the previously mentioned individuals 
will not be sought at any stage. Parents or guardians of these patients will only be 
approached on one occasion to obtain consent.  For the purposes of this study these 
control samples will only be defined as “presumed HIV negative” based on clinical 
examination and history obtained by the treating physician. For the purpose of this study 
we aim to obtain between 25 and 50 control samples. 
 
Laboratory Assays 
 
Peripheral Blood Leukocyte Mitochondrial:Nuclear DNA Ratios 
The protocol to be followed is that described by HCF Côte et al (10). A 500µl whole 
blood sample will be collected in acid-citrate-dextrose and kept at 4°C. Required DNA 
will be extracted from 200 – 300µl of whole blood and purified by means of a Roche 
High Pure DNA extraction kit within 12 hours of phlebotomy. Extracted DNA will be 
stored at -70°C until all collections are completed. For each DNA extract, the nuclear 
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gene for the human polymerase gamma accessory subunit (ASPOLG) and the 
mitochondrial gene, human cytochrome-c oxidase subunit I (CCOI) will be quantified 
separately by real-time PCR using a Roche Light-Cycler, based in the Division of 
Virology, University of Cape Town. Reagents will include Roche Light-Cycler Fast-Start 
DNA Master Hybridization Probe Mix (Roche Applied Science), primers and labelled 
oligonucleotide probes (Roche Applied Science) and Light-Cycler – Control Kit DNA 
(Roche Applied Science), for generation of the standard curves. This method allows for 
expression of the mt:nDNA ratio in PBLs giving a direct count of the average number of 
mitochondrial DNA copies per nuclear DNA copy per leukocyte. 
 
Venous Lactate Measurement 
Venous lactate measurement will be performed on 15µl of fresh whole blood collected 
with the use of a tourniquet and avoidance of fist-clenching or lengthy struggling. This 
blood will be obtained from the same phlebotomy as for the DNA collection and the 
measurements done at point of care using a point-of-care lactate instrument (BM-
Lactate®, Roche Diagnostics GmbH, Mannheim Germany). Collections and 
measurements will be supervised by the principal investigator. Results will be compared 
to the reported range of < 2.1mmol/l for venous blood (15,23). This instrument has been 
correlated with enzymatic wet chemistry lactate methods in adult and paediatric patients.  
 
Statistical Analysis and Study Design 
This study is designed as a cross sectional analysis of mt:nDNA ratios in three separate 
paediatric populations, namely HIV-infected drug naive children, children who have 
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completed 6 – 12 months of uninterrupted HAART and a control population of clinically 
non infected children. All three populations will be age matched. The correlation between 
lactate levels and mt:nDNA ratios in the two HIV infected populations will be assessed 
statistically with the aim of establishing the value of serial lactate measurements in 
patients on HAART as an indirect marker of mitochondrial DNA depletion. Lactate 
levels will not be performed in the control population and a published paediatric 
reference interval will be used as a comparison. During the collection period, lactate 
measurements will be performed, and DNA extracted and frozen daily, until sufficient 
samples have been collected.  For mt:nDNA ratios on the light-cycler, control DNA, 
available as a standard reference material will be used to set up standard curves on the 
instrument for determination of copy numbers as described by Cote et al [9]. Intra and 
inter-assay coefficients of variation will be calculated for the mt:nDNA assay. Data will  
be expressed as means and standard deviations (SD) or median and interquartile ranges 
and means compared using Student’s T-test and Student’s paired T-test in the case of 
longitudinal variables. Multivariate analysis models will be built in consultation with a 
medical biostatistician to search for related variables. Based on the findings of the 
preliminary data analysis, the HIV infected, drug naïve population will be subdivided 
according to CDC and WHO clinical criteria and CD4 / viral load counts to determine the 
correlation between HIV disease severity and mt:nDNA ratios. The drug treated group 
will also be subdivided by drug regimens to ascertain the effect of different regimens on 
mt:nDNA. To aid in analysis of mt:nDNA ratios the mean of the control groups will be 
assumed to represent 100% and the means of the test groups will be expressed as a 
percentage of the control mean as described by Chiappini F.et al (22). 
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Envisaged outputs/outcomes 
It is envisaged that this study will provide a clear indication of the distribution of mt:n 
DNA ratios in children with HIV on HAART in relation to HIV-infected HAART naïve 
children and controls. This will aid in further defining the effect of HIV infection itself on 
mitochondrial DNA numbers and provide information on the effect of different drug 
regimens on this marker. We do not expect lactate levels to correlate well with mt:n DNA 
ratios in the majority of patients on HAART as elevated lactate is associated with a 
critical threshold level of mitochondrial dysfunction and has poor specificity. This has 
been borne out in adult studies. We foresee that this information will be extremely 
valuable in providing the methodology and groundwork for a longer term, outcomes 
based study on the effect of HIV induced mitochondrial DNA depletion and subsequent 
risk for NRTI induced mitochondrial toxicity in South Africa. 
Currently, real-time PCR-based assessment of mitochondrial toxicity exists only as a 
research tool and it is hoped that with a clearer definition of its value it might be 
developed into a cost-effective and reliable management tool, improving overall patient 
management and care. We also hope that further research into the long-term effects of 
HAART in children will be stimulated by this project. 
 
This study will be submitted for journal publication, together with an appropriate 
conference presentation. 
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8. Impact 
Capacity development 
Dr George van der Watt is currently a second year Chemical Pathology registrar (MMed 
Chem Path) at UCT with the NHLS and will be applying basic research principles 
throughout the project. He will be setting up a real-time PCR assay for quantitative 
assessment of human genomic and mitochondrial DNA, currently not available in South 
Africa, and applying it to diagnostic research. The possibility of training scientists and 
technologists in the NHLS in the operation of this technique exists, and is relevant to the 
progressively widening spectrum of applications of real-time PCR. 
 
The clinical-pathological interaction that this study provides between the NHLS 
Divisions of Chemical Pathology and Virology at Groote Schuur Hosptal and the clinical 
Division of Infectious Disease at the Institute for Child Health, Red Cross Childrens’ 
Hospital will aid in promoting a more cohesive, integrated approach to paediatric HIV 
management in our environment. 
 
9. Institutional Approval 
This proposal has been approved by the University of Cape Town Research Ethics 
Committee. Ethics approval reference: 124/2004. 
Separate consent forms for each cohort are attached. 
 
10. Funding  
Source:  NHLS Research Trust. 
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Amount:  R 50 000.00 – approved 
Source:  Department of Infectious Diseases, Red Cross Childrens’ Hospital 
Amount:  R10 000.00-approved 
 
11. Budget 
Calculated for 250 samples including calibration of instruments 
 
Consumables Number of units Unit Cost Price – VAT 
inclusive 
Primers (nDNA) 
Primers 
(mDNA) 
 
Flourescent 
probes (nuclear) 
Flourescent 
probes (mito) 
 
Capillaries 
 
Conrol kit DNA 
 
Fast Start  
1 
 
1 
 
2 
 
 
2 
 
1 set 
 
1 kit 
 
3 kits 
R747.36 
 
R747.36 
 
R11105.10 
 
 
R11105.10 
 
R5253.12 
 
R2209.32 
 
R2166.00 
R747.36 
 
R747.36 
 
R11 105.10 
 
 
R11 105.10 
 
R5 253.12 
 
R2 209.32 
 
R6 498.00 
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reaction mix 
 
 DNA extraction 
kit-250 
 
S-lactate NHLS 
tariff code 4075  
 
 
1 kit 
 
 
250 
 
 
R6737.93 
 
 
R58-17 
 
 
R6 737.93 
 
 
R14 542.50 
  TOTAL R58 945.79 
 
An additional R30 per visit will be provided to all participants in the trial to cover 
transport costs. This is in keeping with standard practice at the HIV clinic. (R4000.00 – 
R5000.00). 
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Abstract 
HIV-infection and the pharmacological treatment thereof have both been shown to affect 
mitochondrial function in a number of tissues and each may cause specific organ 
pathology through specific mitochondrial pathways. HIV has been shown to kill various 
tissue cells by activation of mitochondrial apoptosis, and nucleoside analogues, used 
extensively to treat HIV are known to influence a number of steps affecting 
mitochondrial DNA integrity. This review describes the basic physiology, pharmacology 
and pathophysiology of HIV and the nucleoside analogues regarding mitochondrial 
function, and discusses the progress made in this field with respect to the measurement of 
these effects and the prediction of potential drug toxicity. The review goes on to highlight 
areas in the field that require further research and concludes with a summary of the 
pertinent issues that face us today regarding mitochondrial dysfunction and its 
relationship to HIV-infection. 
 
Introduction 
The success of combination drug highly active antiretroviral therapy (HAART) for 
advanced human immuno-deficiency virus (HIV) infection in 1996 (1) marked the 
beginning of an era that would result in HAART becoming the principal regimen of 
therapy used to treat millions of HIV-infected adults and children around the world. 
Unfortunately the agents used in these multi-drug regimens are not without side-effects,  
and nucleoside reverse transcriptase inhibitors (NRTIs), included in most regimens, are 
responsible for significant morbidity and mortality mostly associated with severe lactic 
acidosis in patients on HAART (2-7). Nucleoside reverse transcriptase inhibitors were 
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already known by the early 1990's, to be mitochondrial toxins causing mitochondrial 
DNA depletion (8), and since then the toxic effects have been well characterized, less 
toxic NRTIs have been developed and the risk factors associated with mitochondrial 
toxicity identified (9). What has however remained elusive is a reliable laboratory marker 
that can identify pre-clinical mitochondrial toxicity and prevent morbidity. More recently, 
HIV itself has emerged as a cause of mitochondrial dysfunction, further complicating the 
diagnosis and management of NRTI associated mitochondrial toxicity. These factors, 
combined with recent data suggesting that NRTIs, in addition may undermine 
mitochondrial DNA integrity, has renewed concern over the long term side affects of 
these agents in patients that could well be exposed to them for life. This review aims to 
cover the progress of knowledge and provide insight into the mechanisms of HIV 
associated mitochondrial dysfunction, describing potential implications for patient 
management, drug development and research in this field.  
  
Objectives 
The objectives of this literature review can be summarized as follows: 
1. Describe the literature search strategy used to identify, include and exclude work 
used to prepare this review.  
2. Background: describe the basic physiology of mitochondrial function and how 
this relates to the pathophysiology of NRTIs and HIV infection regarding 
mitochondrial function. 
3. Describe the history of research in the field of HIV associated mitochondrial 
toxicity, citing important studies that have contributed significantly towards our 
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current understanding of the problem and discussing the major strengths and 
weaknesses of these studies. 
4. Identify areas requiring further research. 
5. Conclude the review.    
 
1. Literature Search Strategy 
Three principal routes were followed to identify and obtain relevant literature cited. 
Firstly, a number of initial landmark studies consisting of original research and published 
in high impact-factor journals were identified. The first of these (10) was identified 
during routine journal review. The references in these papers were then cross referenced 
and evaluated to identify common papers cited that in turn were evaluated to assess their 
contribution to the field. This process yielded a core body of essential literature. Secondly 
the progressive and current literature leading up to the present was regularly searched 
using the Pubmed electronic database at http://www.ncbi.nlm.nih.gov/pubmed/advanced 
using a number of search terms and keywords. With each article identified, related 
articles were searched and reviewed to ensure that new studies were not missed. The third 
source was directly through personal communication with some authors (10-12) and 
through reviewers' comments that directly cited important papers when our own work 
was submitted for publication. Review papers were used where they provided additional 
data such as study comparisons or provided new guidelines. For the balance, original 
investigative papers available through Pubmed were used preferentially and where 
findings overlapped, preference was given to older publications.    
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2. Background
Mitochondria are found in all human cells with the exception of mature red blood cells 
and host a number of essential biochemical reactions largely concerned with fuel 
oxidation and ATP production (13). In addition, mitochondria are intimately involved in 
a number of cellular processes including cell differentiation, signaling, and division, and 
are recognized as being critically involved in programmed cell death or apoptosis and 
ageing (13-15). Mitochondria also contain their own unique circular DNA (mtDNA), an 
evolutionary remnant that at 16,5 kilobases, contains 37 genes that code for 13 
respiratory chain peptides,  2 rRNA’s  and 22 tRNA’s involved in mitochondrial protein 
synthesis (16,17). Most mitochondria contain at least 2 copies of mtDNA and the number 
of mitochondria in cells range from a couple of hundred to hundreds of thousands, in 
tissues with high energy demands such as muscle, renal tubular cells and neurons (17,18). 
Mitochondria and their DNA are maternally inherited, derived directly from thousands of 
maternal oocyte mitochondria. A number of maternally inherited mitochondrial 
cytopathies with specific mutations in the mitochondrial DNA are well described (17). 
Two principles govern the manifestation of inherited mitochondrial disease. Firstly the 
"threshold effect" describes the fact that a critical threshold of dysfunctional 
mitochondria need to be present before a tissue manifests with mitochondrial failure, due 
to the high reserve of oxidative capacity inherent in most tissues. Secondly, mitochondria 
are randomly distributed in the growing zygote in a process known as heteroplasmy. This 
gives rise to the fact that two patients with identical mtDNA mutations may manifest with 
different tissue symptoms due to differences in the diseased mitochondrial load in each 
tissue (17). Mitochondrial DNA is replicated by the enzyme, DNA polymerase gamma, 
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this enzyme that performs both polymerase and exonuclease activities differs from the 
nuclear DNA polymerases in that it is more susceptible to interference by a number of 
nucleotide analogues designed to inhibit HIV reverse transcriptase (19). 
 
NRTIs and Mitochondrial DNA Integrity 
Phosphorylated nucleoside analogues interfere with viral reverse transcriptases by 
actively competing with endogenous nucleotides for incorporation into the growing 
nucleic acid chain. After incorporation they prevent chain elongation as they do not 
contain a 3' hydroxyl group for addition of the next nucleotide (20-22). Examples are 
shown in Figure 1 (prepared by author). 
 
In this manner, NRTIs have been shown to interfere with mitochondrial DNA polymerase 
gamma in vitro (20), causing depletion of mtDNA that is assumed to result in 
mitochondrial dysfunction. Major manifestations of this form of toxicity include 
potentially fatal lactic acidosis, skeletal myopathy, cardiomyopathy, neuropathy, 
pancreatitis and nephrotoxicity principally manifesting as tubulopathy (2,23-30). 
Figure1. Selected endogenous nucleosides and their corresponding antiviral 
drug analogues (differences are highlighted in red) Un
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Although all NRTIs affect mtDNA polymerase gamma, abacavir (ABC) together with 
didanosine (ddI) and stavudine (d4T) have repeatedly been implicated in most severe 
cases of mitochondrial toxicity with fatal lactic acidosis (10,31,32).  
Apart from their direct effect on mtDNA polymerase gamma, nucleoside analogues may 
also compete with endogenous nucleosides for phosphorylation by mitochondrial 
thymidine kinase-2 and also for transport into the mitochondria (33,34). Evidence is now 
emerging that NRTIs may increase the rate of accumulation of mtDNA mutations and 
increased mutations have been demonstrated longitudinally in peripheral leukocytes in 
patients on HAART (35). In addition, Maagaard et al found increased mtDNA deletions 
in skeletal muscle of patients exposed to NRTIs (36) and reduced mitochondrial gene 
expression has  been demonstrated in adipocytes exposed to NRTIs (37,38). Taken 
together this evidence suggests that NRTIs as a group may have far reaching effects on 
mitochondrial function in the short as well as long terms. Regarding predisposing risk 
factors for NRTI mitochondrial toxicity, obese adult females are known to be at increased 
risk (9,39). Furthermore genetic predisposition linked to the mitochondrial DNA 
sequence also appears to play a role. Individuals belonging to mitochondrial haplogroup 
T, that is best characterized as a European mitochondrial lineage have a higher incidence 
of NRTI associated neuropathy (40), and more recently a known T9098C polymorphism 
in the mitochondrial gene for adenosine 5'-triphosphate synthase subunit 6 has been 
associated with severe mitochondrial toxicity in a child after in-utero exposure to AZT 
and 3TC (41).  
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HIV and Mitochondrial Function 
HIV causes apoptosis and cellular death in many tissues, most notably in immune cells 
such as CD4 lymphocytes.  It is not surprising therefore that given the importance of 
mitochondria in regulating cellular apoptosis, that HIV should exploit mitochondrial 
apoptotic pathways to initiate destruction of immune cells involved in the immune 
response against infection. Apoptosis is triggered by two major pathways, the first, 
through exogenous factors that bind cell membrane receptors such as FasL (CD 178) and 
ultimately give rise to cytoplasmic caspase 8 and 10 activation through a cytoplasmic 
signaling pathway leading to apoptosis, and the second through intrinsic factors within 
the cell that trigger cytochrome C and other pro-apoptotic factors to be released from the 
mitochondrial inter-membrane space, that in turn result in caspase 9 activation and 
apoptosis (42,43). HIV is implicated in both of these pathways and the mechanisms are 
illustrated in Figure 2. A number of HIV proteins have been shown directly to activate 
apoptosis and initiate cell death, the most important of these being Env, Nef, Tat and Vpr 
(viral protein R). Env, also known as gp-120, together with Nef and Tat have been shown 
to activate the extrinsic apoptotic pathway through the Fas/FasL receptor(44-46) and Env, 
Nef, Tat and Vpr have all been shown to trigger cytochrome C release from the 
mitochondrial inter-membrane space with subsequent caspase activation through the 
internal pathway. This form of HIV induced apoptosis has been demonstrated in CD4 
cells, haematopoietic cells, cardiac myocytes and neurons (47-50). In addition to the 
direct effect of HIV-1 viral proteins, the massive inflammatory response to HIV and it's 
associated cytokines including tissue necrosis factor-alpha, interleukin 2 and interferon 
alpha are also capable of inducing apoptosis (51-53).  
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It is clear from the above mechanisms that both NRTIs and HIV infection itself directly 
influence mitochondrial function in a number of tissues, HIV by activating mitochondrial 
apoptotic pathways to trigger cell death and NRTIs by directly or indirectly interfering 
with mtDNA integrity. It is therefore not surprising that the clinical manifestations of 
HIV organ pathology and NRTI mitochondrial toxicity should overlap in a number of 
organs with high dependence on mitochondrial function. Examples include neuropathy, 
renal tubulopathy, lipodystrophy and myopathy that can be associated with either agent.   
 
Figure 2. Pathways by which HIV accessory proteins modulate infection-mediated 
apoptosis. 
 Reproduced from Shedlock J, et al. Apoptosis 2008 
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3. Research History of NRTI Toxicity (updated to 2010)
The mechanism of nucleoside analogue interference with mitochondrial DNA 
polymerase gamma and the subsequent depletion of mitochondrial DNA were first 
described in 1990 in early cases of zidovudine (AZT) associated myopathy (8,54,55). In 
1995 Lewis and Dalakas put forward their polymerase gamma hypothesis, based on the 
principle that tissues dependent on high levels of oxidative phosphorylation, where 
NRTIs were incorporated and phosphorylated were most likely to manifest with 
mitochondrial dysfunction (56). With the widespread use of dual NRTIs in HAART 
regimens, and the associated increase in cases of fatal lactic acidosis, researchers looked 
for markers that could predict mitochondrial toxicity. Blood lactate was the obvious 
choice and lactate was and is extensively measured and monitored in large cohorts of 
patients on ART combination regimens. Many of these studies confirmed the increased 
relative risk of lactataemia with d4T and ddI versus AZT based regimens (57). Lactate 
measurement however, as a predictive marker of decompensated mitochondrial toxicity 
was limited by the fact that many adults on NRTI therapy and neonatal recipients of short 
courses of NRTIs of HIV have asymptomatic hyperlactataemia that does not progress to 
decompensated lactataemia (58,59). Also lactate lacks specificity and is influenced by 
technical and physiologic variability (60). 
Another approach was to quantify mtDNA against nuclear DNA using real time PCR 
techniques in peripheral blood leukocytes (PBLs), mainly to avoid invasive tissue 
biopsies. Most techniques employ separation of a leukocyte buffy-coat from platelets 
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because platelets contain mitochondria but not nuclear DNA, which could theoretically 
confound results. Quantitation is usually performed by simultaneous real-time PCR 
amplification with fluorometric detection of a mitochondrial and a nuclear gene and the 
results either expressed as a mitochondrial:nuclearDNA (mt:nDNA ratio) ratio or as 
absolute mtDNA copies per cell, if separate commercial mtDNA and nuclear DNA 
standards are used (61,62).This approach yielded promising data in 2002 when in a 
groundbreaking study, Cotė et al followed 8 HIV-infected hyperlactataemic patients on 
NRTIs longitudinally. They demonstrated significant depletion of PBL mtDNA in these 
patients that improved after cessation of therapy to levels comparable to 47 ART naïve 
HIV-infected patients (10). In addition they reported lower levels of PBL mtDNA in the 
ART naïve HIV-infected patients versus 24 uninfected controls. The strength of this 
study was the fact that it was the first to demonstrate the clinical application of PBL 
mtDNA quantitation as a marker of NRTI mitochondrial toxicity and could be used as a 
laboratory marker for this purpose but its weakness lay in the fact that the patients 
selected for longitudinal study all had overt symptomatic hyperlactataemia on NRTI 
regimens of d4T or d4T/DDI, drugs already known to be associated with increased risk 
for lactataemia (31,63,64). The study was therefore unable to demonstrate whether PBL 
mtDNA could be used to detect pre-symptomatic mitochondrial toxicity before the onset 
of clinical lactataemia or improve on the specificity or sensitivity of lactate as a marker of 
mitochondrial toxicity.  Subsequent to this work a number of studies were conducted to 
evaluate PBL mtDNA in HIV cohorts to answer these questions (12,37,62,65-69). Five of 
these studies confirmed the findings of Cotė et al, namely that PBL mtDNA levels in 
ART naïve HIV-infected patients were depleted versus HIV-negative control groups but 
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not significantly different from ART-exposed patients. Some conflict however existed in 
the small (n=10) cross sectional study by Henry et al (65) that demonstrated no difference 
between HAART  exposed patients and healthy controls and in the longitudinal study of 
Miura et al (67) that demonstrated complete amelioration of PBL mtDNA depletion to 
normal levels with AZT/3TC based HAART, suggesting that HIV was the major cause of 
depleted PBL mtDNA. These findings have more recently been supported by Aldrovandi 
et al who measured PBL mtDNA in babies exposed to NRTIs in utero and as neonates. 
They found that PBL mtDNA was decreased in HIV exposed neonates compared to 
controls but higher in ART/HIV exposed neonates than HIV exposed neonates who were 
not exposed to ART (70). These data suggest that HIV itself is the major contributor 
towards PBL mtDNA depletion and not NRTIs.  Regarding ART exposed patients in 
larger studies, Chiappini (12), Cotė (68), and De Mendoza et al (66) all found lower 
levels of PBL mtDNA associated with d4T, DDI and particularly d4T/DDI combination 
regimens. In the largest of these, a cross sectional study by Cotė et al (68) , 214 ART 
treated individuals exposed to ART for > 4 months clearly demonstrated progressive PBL 
mtDNA depletion with AZT > d4T > ddI > d4T/ddI combination. Today, both d4T and 
ddI are not recommended for first line HAART regimens and are being replaced by safer 
NRTI combination regimens due to their association with mitochondrial toxicity. 
Stavudine is currently only used as a first line drug in resource constrained settings due to 
its lower cost. Paediatric HIV presents additional scenarios where children who do not 
contract HIV are exposed to ART either in utero, during maternal treatment or perinatally 
during PMTCT of HIV. Mitochondrial toxicity associated with PMTCT was highlighted 
in 1999 when 8 HIV-uninfected children in a French cohort exposed to AZT and/or 3TC 
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presented with severe mitochondrial dysfunction, 2 of whom died (71). Subsequent 
prospective cohort studies have been conflicting however, with some reporting evidence 
for an increased incidence of mitochondrial dysfunction up to 18 months post PMTCT 
(72), and others not (73,74). Despite this, transient hyperlactataemia that rarely may 
progress to fulminant lactic acidosis in ART exposed neonates is well known (58,59). 
Based on the outcomes of the South African arm of the Children with HIV Early 
Antiretroviral Therapy (CHER) study (75), treatment guidelines for paediatric HIV have 
been changed and now include ART for all HIV infected children under 12 months of age 
regardless of clinical condition (76). In addition, a move to reduce the use of d4T in 
resource constrained settings is being advocated with substitution of d4T with TDF in 
adults and ABC in children as one of the first line NRTIs (76).    
Due to the conflicting findings with PBL mtDNA measurement, researchers turned their 
attention to tissue mtDNA quantitation. Mitochondrial DNA measured by Cotė et al (77) 
in renal biopsies of patients without HIV, with HIV plus tenofovir (TDF) and with HIV 
but without TDF demonstrated reduced mtDNA levels in both HIV infected groups 
versus uninfected biopsies but no difference between the two HIV groups, suggesting that 
HIV itself also contributed toward mtDNA depletion in renal tissue. Buffet et al (78) 
measured adipose tissue mtDNA in a large cohort of HIV infected individuals with 
lipodystrophy on HAART and found depleted mtDNA levels versus controls and a 
significant association between d4T and ddI and mtDNA depletion. The contribution of 
this study was limited by the fact that only 2 HIV-infected ART naïve patients were 
studied and so the contribution of HIV to adipose tissue mtDNA depletion was not 
assessed (78). The value of tissue mtDNA measurement has been questioned by Kim et al 
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(79), who confirmed Buffets findings of depleted mtDNA in adipose tissue of 
lipoatrophic HAART treated patients but found no decrease in mtDNA dependent 
mitochondrial function and an actual compensatory increase in nuclear driven 
mitochondrial biogenesis, suggesting that mtDNA depletion was not a good marker for 
mitochondrial function. In a cross sectional study by Magaard et al (36), mitochondrial 
DNA was lower in muscle biopsies from 24 patients with HIV on HAART  than 10 ART 
naïve HIV patients, but both groups demonstrated decreased PBL mtDNA compared to 
11 healthy controls  They concluded that PBL mtDNA does not correlate with organ 
mtDNA depletion. Taken together, the measurement of mtDNA in end organs appears to 
deliver similar information to PBL measurements, namely that NRTIs, particularly d4T 
and ddI cause tissue mtDNA depletion, HIV infection may cause depletion independently 
but this is likely to be a tissue dependent phenomenon, and mtDNA levels in tissue do not 
correlate with PBL mtDNA levels or with actual mitochondrial function due to the 
initiation of compensatory mechanisms to preserve essential mitochondrial functions. 
Currently most authors have concluded that measurement of mtDNA in PBLs and tissue 
contribute little toward predicting NRTI induced functional mitochondrial toxicity and 
mtDNA measurements are not used in routine practice though there may still be some 
value in performing serial measurements of PBL mtDNA in at-risk individuals. Due to 
the technical difficulties in obtaining representative, functional mitochondrial specimens, 
simple assays for assessing mitochondrial function are not available and for the most part, 
clinicians are still left with good clinical judgment and lactate measurements as the only 
way to detect early NRTI associated decompensated lactataemia, the most serious side 
effect of these agents. Subsequent to these findings, more recent work has focused on the 
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influence of HIV itself on mitochondrial function, largely to explain the mechanisms of 
HIV induced immunosuppression and organ pathology as discussed above. 
 
4. Further Research 
No study to date has managed to answer a number of pressing questions regarding the 
combination effect of HIV and NRTIs on mitochondrial function. A number of these 
questions can only be answered in longitudinal studies and some are particularly 
applicable to children. Research questions that need to be answered are the following: 
• What are the long term complications of NRTIs, specifically regarding 
mitochondrial DNA integrity and its effect on ageing and end organs with high 
energy requirements and to what extent are tissues able to compensate for NRTI 
induced mtDNA depletion? This question is especially relevant to children who 
will now be exposed these agents for life with typical onset soon after birth. 
• Are the mitochondrial effects of HIV and NRTIs synergistic – in other words are 
patients with severe HIV disease at a higher risk for mitochondrial toxicity from 
NRTIs than patients with less severe HIV disease, and if so which tissues are 
most likely to be affected? This question is especially relevant in resource 
constrained settings where access to ART is limited and many patients have 
more severe disease prior to initiation of treatment with regimens often 
containing d4T. 
• Whilst safer, cost effective ART is developed, is there another laboratory marker 
or tissue specific marker that can be used to identify patients at high risk for 
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NRTI toxicity preemptively so that preventative management can be employed 
in time?  
5. Conclusion
The availability of HAART has made an enormous contribution worldwide to people 
living with HIV and the focus has now shifted to the prevention of long term side effects 
of the drugs used in treatment of this disease. Whilst lipodystrophy and its associated 
metabolic changes are associated with protease inhibitors, the major toxic effect of 
NRTIs is fatal decompensated lactic acidosis due to mitochondrial toxicity. There is also 
growing concern about the cumulative long-term effects of a class of drugs that 
influence mtDNA synthesis and repair.  
Although the availability of safer ART regimens has reduced the incidence of severe 
toxicity, new drugs are often not available in resource constrained settings where the 
majority of people with HIV find themselves, and though measures to limit NRTI 
toxicity such as regimen switching are available, there is a pressing need to implement 
protocols that promote the use of safer first-line NRTIs and restrict the use of d4T. It is 
also crucial to continue further research into the understanding and prevention of ART 
related toxicity, particularly as it relates to children with HIV.  
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Abstract 
Background: Nucleoside reverse transcriptase inhibitors (NRTIs) affect mitochondrial 
DNA polymerase gamma causing significant toxic effects, including fatal lactic acidosis. 
Little is known about mitochondrial DNA (mtDNA) in human immunodeficiency virus 
(HIV) infected children who face a lifetime exposure to these agents. We performed a 
cross sectional observation of mtDNA levels in whole blood in a pediatric population to 
ascertain the relationship between mtDNA, NRTI regimens and parameters of HIV-
infection severity. 
Methods: Whole blood mt:nDNA ratios were determined by real-time PCR in three  
groups: 27 presumed HIV-negative, 89 HIV-infected, NRTI-treated and 62 HIV-infected 
treatment-naive children. Multivariate analysis was used to identify variables 
independently associated with mtDNA depletion. 
Results: Mean mt:nDNA ratios were  lower (P < 0.001) at 77% of control in the HIV-
infected antiretroviral treatment (ART) naïve group and 73% of control in the ART 
group,  but not different between the two HIV-infected groups. Mt:nDNA ratios were 
negatively associated with age (P = 0.029), HIV status (P < 0.0001) and Log10 of the 
HIV-1 viral load (P = 0.035) and positively associated with CD4 % (P = 0.032). A 
stavudine V.S zidovudine based regimen was associated with lower but not significant 
levels of mtDNA (P = 0.08). 
Conclusions: Depletion of whole blood mtDNA in children is associated independently 
with HIV-infection and markers of HIV infection severity, and does not improve with 
either stavudine or zidovudine based ART despite virological control, suggesting that 
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these agents also deplete mtDNA. The long-term consequences of this potentially toxic 
effect remain a cause for concern 
 
 
Introduction 
Nucleoside reverse transcriptase inhibitors form the backbone of all current first line 
ART regimens used to treat paediatric HIV in South Africa. Patients remain on these 
drugs for life, and viral drug resistance and drug toxicity remain problematic. Major side 
effects of NRTIs are the lipodystrophy syndrome and potentially fatal lactic acidosis, in 
addition to organ effects such as myopathy, cardiomyopathy, neuropathy, pancreatitis and 
nephrotoxicity (1-9). 
Mitochondrial toxicity associated with NRTIs as a group is thought to be principally due 
to interference with mitochondrial DNA polymerase gamma, the enzyme responsible for 
mitochondrial DNA replication with resultant depletion in mtDNA (10-12). Stavudine 
(d4T) , a widely used NRTI in cost constrained settings, has repeatedly been implicated 
in cases of mitochondrial toxicity (13-15). Other mechanisms thought to contribute to 
toxicity of these agents include inhibition of mitochondrial thymidine kinase-2 and 
competition between endogenous nucleotides and phosphorylated  NRTIs for transport 
into the mitochondria (16,17). There is now evidence to suggest that these drugs may 
affect the integrity of the mitochondrial genome and not just mtDNA quantity.  
Nucleoside reverse transcriptase inhibitors have been linked to accumulation of mtDNA 
mutations in peripheral blood leukocytes (18) and mtDNA deletions in muscle (19). 
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Decreased expression of mitochondrial genes has also been demonstrated in adipocytes 
exposed to NRTIs even in the absence of reduced mtDNA (20,21).  
 
HIV infection itself also appears to contribute towards mitochondrial dysfunction and a 
number of initial studies looking at NRTI toxicity demonstrated peripheral blood 
leukocyte (PBL) mtDNA depletion in treatment naïve individuals. This has been 
supported by the fact that reduced mtDNA content, decreased oxidative phosphorylation 
activity, and reduced mitochondrial membrane potential have all been found in ART-
naïve patients with HIV, mainly in PBLs (22-28). In addition, evidence of organ 
mitochondrial derangement has been found in skeletal muscle, fat and renal tissue in 
treatment naïve individuals (28-31). The mechanisms underlying HIV's effect on 
mitochondria are less well understood but a number of cytokines associated with 
persistent immune activation together with directly acting viral proteins are thought to 
induce mitochondrial apoptosis with end point reduction in mtDNA and mitochondrial 
function (32,33).  
 
The World Health Organization recommendations on ART in resource-constrained 
settings were followed at our institution during enrolment for the study and between 70% 
and 85% of all HIV-infected children managed at Red Cross Childrens Hospital qualified 
for treatment (34) (Pers comm. B Eley). This however is set to increase with the 
implementation of new guidelines based on data from the South African arm of the 
Children with HIV early antiretroviral therapy (CHER) study (35), that recommends 
ART for all HIV-infected infants under 12 months of age (36). Of the children who 
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required treatment, about 30% were receiving highly active antiretroviral treatment 
(HAART) at the Infectious Diseases Clinic and 30-50% had severe disease or advanced 
immunosuppression (Pers comm. B Eley). Children are theoretically more vulnerable to 
the adverse effects of NRTIs due to a potentially longer exposure and because they are 
growing actively and have higher energy demands. Also, HIV-infection progresses more 
rapidly in children, and ART is indicated at an earlier stage than in adults (37). Many 
children who do not contract HIV are still exposed to ART in utero during maternal 
treatment or perinatally during prevention of mother to child transmission (PMTCT) of 
HIV. Mitochondrial toxicity associated with PMTCT with AZT and/or 3TC has been 
linked to severe mitochondrial dysfunction (38), but subsequent prospective cohort 
studies have been conflicting, with some reporting evidence for an increased incidence of 
mitochondrial dysfunction after PMTCT (39), and others not (40,41). Despite this, 
transient hyperlactataemia that rarely can progress to fulminant lactic acidosis in ART 
exposed neonates is well described (42,43).  The effect of HIV and NRTIs on 
mitochondrial function in children remains poorly understood, the most important 
questions being, whether children with advanced immunological disease are more 
susceptible to drug toxicity or not and what the potential long term effects of NRTIs on 
mitochondrial genome integrity and gene expression are and how these effects could 
manifest over a lifetime exposure to these drugs (44). These are particularly relevant 
questions in South Africa where many children fortunate enough to receive ART have 
advanced clinical disease and many will remain on NRTIs such as d4T for the 
foreseeable future. 
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In South Africa ART availability is limited. Many children qualifying for ART are 
critically ill and clinical differentiation of NRTI-induced mitochondrial toxicity from 
HIV-related disease is difficult. Venous lactate measurements have been suggested to 
screen for NRTI toxicity in adults and children (14,15,45), but representative lactate 
measurements are difficult to obtain. Lactate also has a poor specificity for NRTI 
toxicity. 
 Quantitation of mtDNA in PBLs, using real-time PCR has been investigated in adults as 
a marker of mitochondrial toxicity (13,22,23,27,46). In the first of these studies (13), 
PBL mtDNA depletion was associated with symptomatic hyperlactataemia in 8 adults 
taking d4T. In all patients, mtDNA recovered after interruption of therapy. Three other 
subsequent cross sectional studies have demonstrated similar findings and shown more 
pronounced PBL mtDNA depletion with the use of d4T and didanosine (ddI) based 
regimens together with lower levels of PBL mtDNA in treatment naïve infected adults 
compared to healthy controls (22-24).  
 The objectives of this study were to describe the distribution of whole blood mtDNA, as 
a marker of mtDNA depletion in children, and to assess the effect of NRTI treatment on 
this parameter. We also sought to determine the relationship, if any, between whole blood 
mtDNA and lactate as well as other markers of HIV-infection severity. To our knowledge 
these parameters have not been assessed in a pediatric population. 
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Materials and Methods 
Setting 
HIV-infected children attending the outpatient HIV Clinic under the Division of 
Infectious Diseases at the Childrens Red Cross War Memorial Hospital and presumed 
HIV-negative children attending outpatient surgery at the same institution were enrolled 
into the study between October 2004 and March 2005. Study approval was obtained from 
the Research Ethics Committee of the University of Cape Town. Ethics approval 
reference: 124/2004. 
Patients 
Sixty-two (62) ART-naïve HIV-infected children aged 3.4 – 121.3 months, 89 ART 
exposed children aged 10.2 - 130 months, and 27 presumed HIV-negative children aged 
10.5 – 113 months were included in the cross sectional analysis. Children were assigned 
to the HIV-infected ART-naïve group if they were due for routine management 
phlebotomy, were HIV positive and had never been exposed to any ART regimen other 
than PMTCT. HIV-infected ART-exposed children were included if they had completed 
more than 6 months of uninterrupted single regimen ART and if routine management 
phlebotomy had been requested on the day of their clinic visit. Children attending minor 
outpatient surgery were enrolled in the control group and presumed HIV negative by way 
of no prior physician diagnosis of HIV. Their HIV status was not requested nor tested on 
ethical grounds.  
In the ART-exposed HIV-infected group, 22 children had received a 
zidovudine/lamivudine (AZT/3TC) based regimen with either ritonavir (RIT) (n=12), 
efavirenz (EFV) (n=4) or lopinavir/ritonavir (LPV/RIT) (n=6) constituting the 3rd drug, 
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67 children had received a d4T/3TC based regimen with either RIT (n=23), EFV (n=38), 
LPV/RIT (n=4) or nevirapine (n=2).  
 All children were accompanied by a parent or legal guardian on the day of visitation and 
informed consent was obtained according to the rules of our institution. Age, sex, weight 
and height data were obtained from all children. CD4 count, HIV-1 viral load and type 
and duration of treatment data were obtained for all ART exposed children. CD4 count 
was obtained for all ARV-naïve HIV-infected children and HIV-1 viral load was obtained 
in 23 patients in this group. 
 
Blood sampling and data collection 
Anthropometric data: Age, sex, height and weight data were analyzed using Epi Info™ 
(2004/09/07) software based on the CDC/WHO 1978 reference to estimate weight for 
height Z-scores. 
 
Blood sampling: Children were restrained, when necessary by an assistant during routine 
phlebotomy and free flowing venous blood was collected without the use of a tourniquet. 
A phlebotomy was arbitrarily classified as difficult if more than 1 minute of crying or 
struggling against restraint occurred before blood was obtained. In the control group, 
blood was obtained at the placement of a routine management intravenous catheter after 
induction of general anesthesia.  
Lactate: Lactate was measured on whole blood using a portable, lactate analyzer (BM-
Lactate®, Roche Diagnostics GmbH, Mannheim Germany) by enzymatic reflectance 
photometry. The instrument correlates with reference methods (47) and quality control 
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was performed daily using control solutions. Values > 2.1mM were considered to be 
elevated (15,42). Lactate was not measured in the control group as their phlebotomy 
conditions were considered non-representative. 
HIV-1 Viral load and CD4 count: Leukocytes for CD4 counts were prepared using 
ImmunoPrep™ Reagent System, CD4 and CD45 cells were labeled using  
FlowCare™PLG CD4 Reagent and CD4 counts determined on a Beckman Coulter® 
Epics-XL-MCL flow-cytometer ( Beckman Coulter Ireland, Inc).RNA for HIV-1 viral 
loads was extracted by a Nuclisens®  easyMag™ system and viral load determined using 
a Nuclisens® Easy-Q-HIV-1 v1.1 analyzer ( bioMérieux bv, NL-5281, RM Baxtel, The 
Netherlands). 
 
Quantitation of Mitochondrial DNA by Real-Time PCR 
DNA Preparation: 0.5mL blood collected into K-EDTA BD Vacutainer ® tubes was 
stored at room temperature until same-day DNA extraction. Total DNA was extracted 
from 200µL whole blood using a Roche High Pure PCR Template Preparation kit (Roche 
Diagnostics) into 200µL elution buffer. Extracted DNA was stored at -20Ċ until assayed. 
 
MtDNA quantitation: mtDNA was quantified using an in-house method based on that 
described by Cŏtė et al (13). Briefly, small regions of the nuclear gene for human 
polymerase gamma 2 accessory subunit (ASPOLG-2), and the mitochondrial gene human 
cytochrome-c oxidase subunit 1 (COX-1) were quantified separately by real-time 
quantitative PCR on a Roche Light Cycler. This system utilises fluorescence resonance 
energy transfer technology with 3’fluorescein-labeled and 5’ LC-Red 640-labeled 
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oligonucleotide hybridization probes to quantify the PCR reaction. Control DNA 
prepared from pooled DNA from each of the 27 controls, was used to set up both the 
nuclear and mitochondrial gene standard curves and the mt:nDNA ratio was arbitrarily 
set at 1. All PCR reactions were performed in duplicate. Inter-assay coefficients of 
variation for this assay, derived from 2 patient controls repeated in 19 consecutive runs 
over 5 days were 5.1% for the mitochondrial gene, 7.4% for the nuclear gene and 8.5% 
for the mt:nDNA ratio, respectively. 
 
Statistical analysis 
Results are expressed as means and standard deviations (SD) or median and interquartile 
range. Means were compared with Student’s T-test and Student’s paired T-test in the case 
of longitudinal variables. Type I error was set at 5%. Multivariate analysis models were 
built using Stata version 8.0 software with statistical uncertainty estimated from 95% 
confidence intervals. 
 
Results 
Fundamental study group characteristics are depicted in Table 1 (p73) and laboratory 
parameters compared in Figure 1 (p74). Children in the ART group received HAART for 
a median of 11.8 months with 64% demonstrable suppression of viral replication (HIV-1 
viral load < 400 copies/mL). As expected the efficacy of ART was further evidenced by 
the fact that treated children had significantly higher CD4 percentage counts and 
improved weight for height Z scores compared to ART-naïve HIV-infected children. 
Mean lactate levels were not significantly different between untreated (2.1 + 0.6 mmol/L 
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and treated HIV-infected patients (2.1 + 0.5 mmol/L). As expected, difficult phlebotomy 
was associated with elevated lactate in children from both groups (2.5 + 0.5mmol/L, P < 
0.0001). No cases of symptomatic lactic acidosis or lactate > 5mmol/L were encountered. 
 Mitochondrial:nuclearDNA ratios between study groups are depicted in Figure 2 ( p75). 
The mean mt:nDNA ratio in presumed HIV-negative control group (n = 27) was 1.13 + 
0.22. If this value was assumed to represent 100%, then the mt:nDNA ratio in the ARV-
naïve HIV-infected group (n = 62) was 77% of control (0.87 + 0.3, P < 0.0001) and  73% 
of control (0.82 + 0.23, p < 0.0001) in the ART-treated HIV-infected group (n=89) 
respectively. Although the mean ratio was lower in the ART treated group, there was no 
significant difference in mt:nDNA ratios between ARV-naïve and ART treated HIV-
infected children (P = 0.242). In the ART treatment group, depicted in Figure 3, a d4T 
based regimen was associated with a lower, but not significant level of mtDNA (P = 
0.08) when compared to an AZT based regimen.  
 
Multivariate analysis 
Multivariate analysis of data obtained from HIV-infected children is depicted in Table 2 
(p77). As expected from prior data, mt:nDNA ratios were independently negatively 
associated with HIV status (p < 0.001) in all analyses and no association could be found 
between mt:nDNA ratios and NRTI treatment as a whole, absolute CD4 counts or lactate 
levels. 
In the model looking specifically at children with HIV on ART depicted in Table 3 (p78), 
there was a significant negative association between mitochondrial DNA depletion and 
age (P = 0.018) and the Log10 of the HIV-1 viral load (P = 0.044), furthermore this model 
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demonstrated a significant positive association between CD4 percentage of total 
lymphocyte count (P = 0.032) and mitochondrial DNA. We were concerned that the 
increase in mtDNA seen with effective viral control might be a proxy measure of 
increased lymphocytes as a percentage of total leukocytes and for this reason we 
deliberately included this parameter to correct for this possible confounding effect. 
Multivariate analysis in this group again confirmed lower mtDNA levels associated with 
the use of a d4T based regimen. 
 
 Discussion 
The data, derived from a large cohort of subjects demonstrates that mtDNA is 
significantly depleted in whole blood of ART-naïve HIV-infected children as measured 
by real-time PCR and that this depletion was present before institution of ART. Depletion 
of mtDNA is associated independently with HIV-infection and correlated with markers of 
infection severity, namely increasing HIV-1 viral load and decreasing CD4 percentage 
and is not influenced by total lymphocyte depletion. Furthermore mtDNA levels did not 
change significantly after a median of 11.8 months of HAART, despite good evidence for 
successful suppression of viral replication and clinical improvement. Stavudine based 
regimens were associated with lower mtDNA levels compared to AZT based regimens 
but the difference in children did not approach significance. No cases of clinically 
suspected NRTI toxicity were detected during the study. 
 
A number of limitations were present in the study. Firstly, mt:nDNA ratios were 
determined in whole blood containing platelet mitochondria together with leukocyte 
U
ive
rsi
ty 
Of
 C
ap
e T
ow
n 
 69 
nuclear and mitochondrial DNA and secondly, HIV status was not confirmed in the 
control group. Both factors could potentially increase the distributions obtained for 
mtDNA in each group, reducing the number of statistical associations. In this study, 
sample volumes were too small to effectively separate a buffy coat for PBL DNA 
extraction and so whole blood was used. In addition, a published reference interval for 
lactate was used resulting in an abnormally high percentage of hyperlactataemia or 
suggesting poor phlebotomy technique. This stresses the requirement for in-house 
reference ranges, particularly for lactate in a paediatric setting and highlights problems 
associated with extrapolating published reference intervals and cutoffs.  
 
In agreement with adult based studies, this work has demonstrated that mtDNA depletion 
is present in children with HIV and that this depletion is dependent on HIV-infection 
severity and does not improve with ART containing NRTIs. This depletion most likely 
has a dual etiology. Firstly due to the known inhibitory effect of NRTIs on mitochondrial 
DNA polymerase gamma and secondly, that associated with HIV-infection itself. How 
the mitochondrial effects of NRTIs, particularly d4T, which is still widely used in South 
Africa, will manifest in the long term remains to be seen and longitudinal studies in 
children are needed in this regard. Due to the fact that both NRTIs and HIV may 
influence the level of whole blood mtDNA, the value of this, or other blood based 
mtDNA quantification markers to predict or diagnose life threatening NRTI toxicity with 
lactic acidosis is doubtful.  Regular clinical assessment may still be the most viable way 
to prevent drug related fatalities together with the implementation of regimens that 
employ safer first-line NRTIs and limit the use of d4T (36). This is especially relevant to 
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resource constrained settings, where the majority of children who face a lifetime 
exposure to these drugs are to be found. 
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Table 1: Fundamental Study Group Characteristics 
 
  
Controls, presumed 
HIV negative 
 
HIV-infected 
ART naïve  
 
HIV-infected  
on ART 
n 27 62 89 
Age in months 
Median 
Interquartile range 
 
 
58 
36 – 73 
 
36 
17 - 77 
 
33 
19 - 62 
Weight for height Z-
score 
Median 
Interquartile range 
 
 
 
-0.44 
-0.97 - +0.34 
 
 
-0.87 
-1.47 - -0.03 
 
 
0.28 
-0.42 - +0.90 
Gender 
Proportion male 
 
 
48% 
 
42% 
 
56% 
CD4% of total  
lymphocyte count 
Mean 
SD 
 
 
 
N/A 
 
 
15.3 
8.7 
 
 
23.3 
9.2 
Duration of HAART in 
months 
Median 
Interquartile range 
 
 
 
N/A 
 
 
N/A 
 
 
11.8 
6.3 – 17.4 
HIV-1 viral load < 400 
copies/mL, n (%) 
 
 
N/A 
 
N/A 
 
56 (64%) 
NRTI exposure – n (%) 
d4T/3TC 
AZT/3TC 
 
 
N/A 
N/A 
 
 
N/A 
N/A 
 
 
67 (75%) 
22 (25%) 
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Figure 1: Comparative laboratory parameters between ART (n=89) and non-ART 
(n=66) groups of HIV-infected children. Box-and-whisker plots: whiskers = non-outlier 
range, box = 25th to the 75th percentiles, marker = median; *** denotes P < 
0.0001
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Figure 2: Mitochondrial:nuclearDNA ratios between study groups. Box-and-whisker 
plots: whiskers = non-outlier range, box = 25th to the 75th percentiles and the marker = 
median (50th centile); *** denotes P < 0.001, compared to control.  
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 Figure 3: Mitochondrial:nuclearDNA ratios between children treated with d4T VS 
an AZT based regimen. Box-and-whisker plots: whiskers = non-outlier range, box = 
25th to the 75th percentiles and the marker = median (50th centile); P denoted on the 
plot. 
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Table 2: Multivariate analysis data assessing impact of HIV on 
Mitochondrial:Nuclear DNA ratio, adjusted for co-variates (n = 172) 
 
Attribute Co-efficient 95% CI p-value 
HIV-infected -0.26 (-0.38 – -0.14) <0.001 
Female sex 0.07 (-0.01 – 0.15) 0.079 
Per-year increase in age -0.01 (-0.03 – 0.00) 0.084 
Per-unit increase in weight for 
height Z-score 
0.02 (-0.01 – 0.05) 0.144 
On HAART -0.07 (-0.16 – 0.02) 0.143 
Constant 1.17 (1.04 – 1.29)  
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Table 3: Multivariate analysis data assessing predictors of Mitochondrial:Nuclear 
DNA ratio in HIV-infected patients on HAART, adjusted for co-variates (n = 80)  
 
Attribute Co-efficient 95% CI p-value 
Female sex 0.03 (-0.07 – 0.12) 0.586 
Per-year increase in age -0.03 (-0.05 – 0.00) 0.018 
Per year treatment duration 0.002 (-0.06 – 0.062) 0.928 
d4T based regimen -0.09 (-0.19 – 0.01) 0.084 
Per-unit increase in weight for height 
Z-score 
0.01 (-0.02 – 0.04) 0.517 
Log10 most recent HIV-1 viral load -0.04 (-0.08 – 0.00) 0.044 
Per 10% increase in CD4% of total 
lymphocyte count 
0.07 (0.01 – 0.13) 0.032 
Per 10% increase in lymphocyte% of 
white cell count 
0.00 (-0.03 – 0.04) 0.787 
Constant 0.83 (0.50 – 1.17)  
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PART D 
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Informed Consent Forms for the Study: 
 
 
Mitochondrial:Nuclear DNA Ratios in Peripheral Blood Leukocytes and 
Lactate in Human Immunodeficiency-virus Infected Children on 
Antiretroviral Drug Regimens 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
September 2004 
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Mitochondrial:Nuclear DNA Ratios in Peripheral Blood Leukocytes and Lactate in Human 
Immunodeficiency-virus Infected Children on Antiretroviral Drug Regimens 
 
Investigators: George F van der Watt*, Howard Henderson*, Brian Eley †. 
*Division of Chemical Pathology, Groote Schuur Hospital, University of Cape Town.  
† Divisions of Paediatric Medicine and Infectious Diseases, Red Cross Childrens' Hospital, University of Cape 
Town 
 
Information for Participating Patients 
This study is being conducted to investigate specific side effects, due to Antiretroviral Drug treatment for HIV infection in children. 
Drug treatment may affect energy metabolism in certain patients by interfering with mitochondrial function. In the study we will 
measure the amount of mitochondrial DNA in white blood cells in healthy children and in HIV infected children to better understand 
these side effects. By learning more, we hope to be able to provide safer treatment for children with HIV infection.  
Should you have any questions, you are free to contact Dr George van der Watt at Groote Schuur Hospital: Tel 021 404435 or Dr 
Brian Eley at Red Cross Hospital: Tel 021 6585111 
 
Consent for DNA Analysis, Storage and Lactate Measurement: Drug Treatment Patient Consent  
 
1.  I _____________________________________  (legal parent or guardian) hereby give permission that blood may be taken and 
genetic material and plasma analysed, to try and determine the level of side effects due to antiretroviral drugs that may occur in 
_______________________________________  (patient) who will be receiving this medication as treatment for HIV infection 
2.  I understand that the genetic material will be obtained from blood    (mark if applicable) 
 
 
3.  I request that no portion of the sample be stored for later use    (mark if applicable) 
                                                 OR                                                                                                                 
 I request that a portion of the sample be stored indefinitely for:    
o possible re-analysis 
o research purposes, subject to the approval of the University of Cape Town 
Research Ethics Committee and that any information obtained will remain 
confidential 
 
 
4. I request that the results of the analysis carried out on this sample of stored biological material will be made known to me via my 
doctor, in accordance with the relevant protocol    
 
5. I have been informed that: 
o the analysis is specific for measuring the amount of DNA and cannot determine the complete 
genetic makeup of an individual    
o the investigators are under obligation to respect medical confidentiality   
o where biological material is used for research purposes there may be no benefit to me or to my 
child    
 
 
6. I UNDERSTAND THAT I MAY WITHDRAW MY CONSENT FOR ANY ASPECT OF THE ABOVE AT ANY TIME 
WITHOUT THIS AFFECTING MY OR MY CHILDS FUTURE MEDICAL CARE    
 
 
7. ALL THE ABOVE HAS BEEN EXPLAINED TO ME IN A LANGUAGE THAT I UNDERSTAND AND MY QUESTIONS  
       ANSWERED   
  
 Parent or legal Guardian: Name   _________________________                               Date: ________/____/____ 
              Sign     _________________________                                           yyyy      mm     dd 
 
Informed Consent obtained by: Name _________________________ 
                      Sign   _________________________ 
 
• This consent form is to be translated into Afrikaans and Xhosa 
• A councillor is to explain and obtain each informed consent 
• This form is to be retained by the Parent/Guardian of the Patient. A duplicate copy is to be kept in the patients 
folder 
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Mitochondrial:Nuclear DNA Ratios in Peripheral Blood Leukocytes and Lactate in Human 
Immunodeficiency-virus Infected Children on Antiretroviral Drug Regimens 
 
Investigators: George F van der Watt*, Howard Henderson*, Brian Eley †. 
*Division of Chemical Pathology, Groote Schuur Hospital, University of Cape Town.  
† Divisions of Paediatric Medicine and Infectious Diseases, Red Cross Childrens' Hospital, University of Cape 
Town 
 
Information for Participating Patients 
This study is being conducted to investigate specific side effects, due to Antiretroviral Drug treatment for HIV infection in children. 
Drug treatment may affect energy metabolism in certain patients by interfering with mitochondrial function. In the study we will 
measure the amount of mitochondrial DNA in white blood cells in healthy children and in HIV infected children to better understand 
these side effects. By learning more, we hope to be able to provide safer treatment for children with HIV infection.  
Should you have any questions, you are free to contact Dr George van der Watt at Groote Schuur Hospital: Tel 021 404435 or Dr 
Brian Eley at Red Cross Hospital: Tel 021 6585111 
 
Consent for DNA Analysis, Storage and Lactate Measurement: ARV Naïve Patient Consent  
 
 
1.  I _____________________________________ (legal parent or guardian) hereby give permission that blood may be taken and 
genetic material and plasma analysed, to measure the effect of HIV infection on mitochondrial DNA that may occur in 
_______________________________________  (patient) 
 
2.  I understand that the genetic material will be obtained from blood    (mark if applicable) 
 
3.  I request that no portion of the sample be stored for later use    (mark if applicable) 
                                                 OR                                                                                                                 
 I request that a portion of the sample be stored indefinitely for:    
o possible re-analysis 
o research purposes, subject to the approval of the University of Cape Town 
Research Ethics Committee and that any information obtained will remain 
confidential 
 
4. I request that the results of the analysis carried out on this sample of stored biological material will be made known to me via my 
doctor, in accordance with the relevant protocol    
 
5. I have been informed that: 
o the analysis is specific for measuring the amount of DNA and cannot determine the complete 
genetic makeup of an individual    
o the investigators are under obligation to respect medical confidentiality   
o where biological material is used for research purposes there may be no benefit to me or to my 
child    
 
 
6. I UNDERSTAND THAT I MAY WITHDRAW MY CONSENT FOR ANY ASPECT OF THE ABOVE AT ANY TIME 
WITHOUT THIS AFFECTING MY OR MY CHILDS FUTURE MEDICAL CARE    
 
 
7. ALL THE ABOVE HAS BEEN EXPLAINED TO ME IN A LANGUAGE THAT I UNDERSTAND AND MY QUESTIONS  
       ANSWERED   
  
 Parent or legal Guardian: Name   _________________________                               Date: ________/____/____ 
              Sign     _________________________                                           yyyy      mm     dd 
 
Informed Consent obtained by: Name _________________________ 
                      Sign   _________________________ 
 
• This consent form is to be translated into Afrikaans and Xhosa 
• A councillor is to explain and obtain each informed consent 
• This form is to be retained by the Parent/Guardian of the Patient. A duplicate copy is to be kept in the patients 
folder 
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Mitochondrial:Nuclear DNA Ratios in Peripheral Blood Leukocytes and Lactate in Human 
Immunodeficiency-virus Infected Children on Antiretroviral Drug Regimens 
 
Investigators: George F van der Watt*, Howard Henderson*, Brian Eley †. 
*Division of Chemical Pathology, Groote Schuur Hospital, University of Cape Town.  
† Divisions of Paediatric Medicine and Infectious Diseases, Red Cross Childrens' Hospital, University of Cape 
Town 
 
Information for Participating Patients 
This study is being conducted to investigate specific side effects, due to Antiretroviral Drug treatment for HIV infection in children. 
Drug treatment may affect energy metabolism in certain patients by interfering with mitochondrial function. In the study we will 
measure the amount of mitochondrial DNA in white blood cells in healthy children and in HIV infected children to better understand 
these side effects. By learning more, we hope to be able to provide safer treatment for children with HIV infection.  
Should you have any questions, you are free to contact Dr George van der Watt at Groote Schuur Hospital: Tel 021 404435 or Dr 
Brian Eley at Red Cross Hospital: Tel 021 6585111 
 
Consent for DNA Analysis and Storage: Control Group Consent  
 
 
1.  I _____________________________________ (legal parent or guardian) hereby give permission that blood may be taken and 
genetic material analysed, for determination of the normal level of mitochondrial DNA in  
_______________________________________  (patient) 
 
2.  I understand that the information obtained will be compared to that from HIV infected children to determine the effect of HIV and 
its treatment on mitochondrial DNA in these children    (mark if applicable) 
 
3.   I understand that the genetic material will only be obtained from blood taken during routine management during his/her stay at 
Red Cross Childrens' Hospital     (mark if applicable) 
 
4.  I request that no portion of the sample be stored for later use    (mark if applicable) 
                                                 OR                                                                                                                 
 I request that a portion of the sample be stored indefinitely for:    
o possible re-analysis 
o research purposes, subject to the approval of the University of Cape Town 
Research Ethics Committee and that any information obtained will remain 
confidential 
5. I request that the results of the analysis carried out on this sample of stored biological material will be made known an explained to 
me at my request, in accordance with the relevant protocol    
 
6. I have been informed that: 
o the analysis is specific for measuring the amount of DNA and cannot determine the complete 
genetic makeup of an individual    
o the investigators are under obligation to respect medical confidentiality   
o where biological material is used for research purposes there may be no benefit to me or to my 
child    
 
7. I UNDERSTAND THAT I MAY WITHDRAW MY CONSENT FOR ANY ASPECT OF THE ABOVE AT ANY TIME 
WITHOUT THIS AFFECTING MY OR MY CHILDS FUTURE MEDICAL CARE    
 
8. ALL THE ABOVE HAS BEEN EXPLAINED TO ME IN A LANGUAGE THAT I UNDERSTAND AND MY QUESTIONS  
       ANSWERED   
  
 Parent or legal Guardian: Name   _________________________                               Date: ____/____/_________ 
              Sign     _________________________                                          dd      mm     yyyy 
 
Informed Consent obtained by: Name _________________________ 
                      Sign   _________________________ 
 
• This consent form is to be translated into Afrikaans and Xhosa 
• A councillor is to explain and obtain each informed consent 
• This form is to be retained by the Parent/Guardian of the Patient. A duplicate copy is to be kept in the patients 
folder 
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Ethics Approval Letter 
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Technical Appendix 
 
Development of the RT-PCR method for determination of mt:nDNA ratios in whole 
blood. 
 
1. DNA extraction 
DNA was extracted from 200 – 300µl of whole EDTA blood and purified by means of a 
Roche High Pure DNA extraction kit within 12 hours of phlebotomy. Extracted DNA 
was stored at -70°C until all collections were completed.  
 
2. Design of primers and hybridization probes 
For each DNA extract, the nuclear gene for the human polymerase gamma accessory 
subunit (ASPOLG) – genebank accession number AF 142992, and the mitochondrial 
gene, human cytochrome-c oxidase subunit I (COX 1) – genebank accession number  NC 
001807 (mt complete genome region 5905 – 7446) were analysed on the NCBI gene 
database http://www.ncbi.nlm.nih.gov and the reported primers, and oligonucleotide 
probes checked to exclude errors before ordering the probes and primers. Oligo ™ 
software was used to check the position of primers, size the PCR product, position of 
oligonucleotide probes, exclude palindromic sequences within primers, melting point of 
primers, likelihood of primer-dimer formation and to ensure that the 3' end of each primer 
did not end on a 3rd wobble position with likely polymorphisms.  
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Human polymerase gamma accessory subunit (ASPOLG) sequence with highlighted 
regions delineated below  
 
5'TGGTGGCTTGTTGGGATCCGTTGAGTGATGGGAGAGTGTGCTCTTTAACTTCGGAGAGAGATGCGCTCT 
CGTGTAGCCGTCAGGGCCTGCCATAAGGTCTGCAGGTGCCTGTTGTCTGGGTTTGGGGGTCGAGTAGATGC 
GGGGCAGCCGGAGCTGTTGACGGAAAGGAGTAGCCCCAAAGGAGGGCATGTGAAGTCGCACGCGGAGCTC 
GAGGGGAACGGCGAGCACCCAGAAGCCCCCGGGTCTGGAGAGGGAAGCGAGGCGCTGTTAGAGATCTGTC 
AGAGAAGGCATTTCCTAAGTGGAAGCAAGCAGCAGCTTAGCCGGGATTCTCTTCTGAGTGGGTGCCACCC 
CGGCTTCGGACCCTTGGGCGTAGAGTTGCGGAAGAACCTGGCCGCAGAATGGTGGACCTCGGTGGTGGTG 
TTCAGGGAGCAGGTATTCCCGGTGGACGCCCTCCACCACAAACCAGGCCCTTTGCTACCCGGGGACAGTG 
CCTTCAGGTTAGTTTCTGCAGAAACTCTACGCGAAATCTTGCAAGACAAAGAGCTGAGTAAGGAACAGCT 
-3’ 
Start codon 
Forward Primer 
Reverse Primer 
Flourescein labeled oligo 
LC-Red 640 labeled oligo 
 
 
Human mitochondrial gene, cytochrome-c oxidase subunit I (COXI) sequence with 
highlighted regions delineated below  
 
ATGTTCGCCGACCGTTGACTATTCTCTACAAACCACAAAGACATTGGAACACTATACCTATTATTCGGCG 
CATGAGCTGGAGTCCTAGGCACAGCTCTAAGCCTCCTTATTCGAGCCGAGCTGGGCCAGCCAGGCAACCT 
TCTAGGTAACGACCACATCTACAACGTTATCGTCACAGCCCATGCATTTGTAATAATCTTCTTCATAGTA 
ATACCCATCATAATCGGAGGCTTTGGCAACTGACTAGTTCCCCTAATAATCGGTGCCCCCGATATGGCGT 
TTCCCCGCATAAACAACATAAGCTTCTGACTCTTACCTCCCTCTCTCCTACTCCTGCTCGCATCTGCTAT 
 
Start codon 
Forward Primer 
Reverse Primer 
Flourescein labeled oligo 
LC-Red 640 labeled oligo 
 
 
3. PCR reactions and Light Cycler Settings 
Real-time PCR was performed on a Roche Light-Cycler. A number of PCR reactions 
were assessed to ascertain the optimum PCR reaction temperatures and reagent 
concentrations to yield optimum standard and melting curves during the RT –PCR 
reaction for each gene. Final reagent mix is listed as follows: 
ASPOLG-2 and CCO1  
• 1µM Forward Primer  
• 1µM Reverse Primer  
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• 0.4µM 5' LC-Red oligonucleotide
• 0.2µM 3' Fluorescein oligonucleotide
• 4µL Master Mix, Roche™ (consisting of Taq polymerase, bufferm MgCl, dNTP's
containing dATP instead of dTTP)
• 5 µL sample DNA
• dH2O to a final volume of 20µL
Final PCR conditions used were. 
• 1 activation cycle: 90°C for 10 minutes
• 45 PCR cycles: denature: 95°C for 0 seconds; anneal: 60°C for 10 seconds with a
single acquisition; extension: 72°C for 5 seconds
• Melting curves were used to evaluate PCR efficacy and continuity between runs
as follows: denature: 95°C for 0 seconds; anneal: 55°C for 30 seconds followed
by continuous acquisition of signal during a melt up to 80°C at a slope of
0.1°C/second
• Cooling cycle to reach 40°C for 30 seconds before termination
Data Analysis 
Data was analysed using the second derivative maximum without baseline adjustment. 
Fluorescence was detected at F2/Back F1 to reduce background noise 
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4. Standard Curves, quantitation of data and determination of the mitochondrial 
nuclear DNA ratio 
 
Once the PCR reactions had been optimized, a control human DNA sample was prepared 
as follows: 
• Five µL aliquots of extracted DNA from 27 healthy controls were pooled and the 
number of nuclear genome equivalents (NGEs) determined in the control mix 
•  A standard curve for the nuclear gene ASPOLG-2 was set up usingLight Cycler 
Control Kit DNA known to contain 15ng/µL of human DNA. Assuming that 
1NGE = 3 pg of DNA this solution was calculated to contain 5000 NGEs /µL. 
This solution was then used to set up a standard curve for ASPOLG-2 ranging 
from 25 to 25 000 NGEs per PCR reaction 
• This ASPOLG-2 standard curve thus generated was then used to determine the 
NGE value in the pooled control mix – The pooled control mix was thus 
calculated to contain 40 000 NGE's/5µL 
 
The control pooled human DNA thus obtained containing 40 000 NGEs/5µL was then 
used to set up standard curves for ASPOLG-2 in the range of 40 to 40 000 NGE's/5µL 
DNA per PCR reaction as demonstrated in Figure 1. 
Because the amount of mtDNA in the pooled control was unknown it was arbitrarily 
assigned a value equivalent to the NGE value and so, the same control DNA was used to 
set up a standard curve for the mitochondrial COX1 gene using the same numerical 
values. 
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The mitochondrial/nuclear DNA ratio of the control mix was therefore arbitrarily set at 1 
and every subsequent sample tested compared to this arbitrary ratio. 
5. Determination of test sample mt:nDNA ratios
All RT-PCR reactions were performed in duplicate and the mean of two runs used. For 
each run on each day a new standard curve for each gene using 4 standards was generated 
in duplicate and test samples read off the standard curves. 
The mean value for the mitochondrial gene divided by the mean value for the nuclear 
gene gave the calculated mt:nDNA ratio in each case.  
Figure 1. Standard curve replicates, linear regression of standard curves and 
melting curve replicates of the nuclear ASPOLG gene (top) and 
mitochondrial COX 1 gene (bottom) used to determine mt:nDNA ratios in 
test samples  
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A low and a high control taken from patient samples was included in each run and used 
to calculate the inter assay CV for each gene, a total of 19 separate runs were performed 
over 5 days in the study. Inter assay CVs were 5.1% for the mitochondrial gene, 7.4% for 
the nuclear gene and 8.5% for the mt:nDNA ratio, respectively. 
Intra-assay CV was not calculated. 
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Study Subject Raw Data 
The following tables contain pertinent patient raw data divided into the following 
cohorts 
Cohort A: HIV-infected patients, naïve to antiretroviral treatment 
Cohort B: HIV-infected patients treated with antiretrovirals 
Cohort C: Presumed HIV negative controls 
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Cohort A: HIV-infected patients, naïve to antiretroviral treatment: 1 
 
 
 
 
 
 
 
 
 
 
 
 
Cohort A: HIV-infected patients, naïve to antiretroviral treatment: 2 
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Cohort A: HIV-infected patients, naïve to antiretroviral treatment: 3 
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Cohort A: HIV-infected patients, naïve to antiretroviral treatment: 4 
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Cohort B: HIV-infected patients treated with antiretrovirals: 1 
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Cohort B: HIV-infected patients treated with antiretrovirals: 2 
Cohort B: HIV-infected patients treated with antiretrovirals: 3 
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Cohort B: HIV-infected patients treated with antiretrovirals: 4 
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Cohort B: HIV-infected patients treated with antiretrovirals: 5 
 
 
Cohort B: HIV-infected patients treated with antiretrovirals: 6 
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Cohort C: Presumed HIV negative controls: 1 
 
 
Cohort C: Presumed HIV negative controls: 2 
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Instructions for Authors 
Journal: Clinical Chemistry 
The following data was obtained online at 
http://www.clinchem.org/info_ar/info_authors.shtml#manprep and consists of an extract 
pertinent to the preparation of manuscripts.  
Note: Data taken directly from website – spelling and grammar have not been formatted to English (UK). 
Manuscript Preparation  
• Author Contribution Requirements
• General Guidelines
• Journal Categories
• Title Page
• Abstract
• Text
• Disclosures/Conflict of Interest
• Acknowledgements
• References
• Tables
• Figure Captions
• Figures
• Color
• Supplemental Data
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Author Contribution Requirements  
Manuscripts are considered for publication with the understanding of the following:  
1. Each author has participated significantly in the work in a substantive way and is
prepared to take public responsibility for its content;
Each listed author must have: 
2. Participated in conception, design, analysis, or interpretation;
3. drafted or critically revised the manuscript; and
4. read and approved the final submitted manuscript and revisions.
Any change in authors and/or contributors after initial submission must be approved by 
all authors. This applies to additions, deletions, change of order to the authors, or 
contributions being attributed differently.  
Any alterations made to the manuscript after submission must be approved by the editor. 
Authors may upload the request letter to the online submission system as a supplemental 
file or send the letter via e-mail to the Clinical Chemistry editorial office; 
clinchemed@clinchem.aacc.org . The editor may contact any of the authors and/or 
contributors to ascertain whether they have agreed to any alteration.  
1. The International Committee of Medical Journal Editors (ICMJE) Uniform
Guidelines for Manuscripts Submitted to Biomedical Journals specifically state
that “all contributors who do not meet the criteria for authorship, such as a person
who . . . provided purely writing assistance" be named in the acknowledgments.
2. Important contributions to an article should be recognized and appropriately
attributed in that article.
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Good medical writers and editors can make valuable contributions to the 
publication process, often improving the clarity of the communication, 
broadening the scope of literature review, providing an extra level of data review, 
adding balance and objectivity, and shortening the time needed for manuscript 
development.  
The American Medical Writers Association (AMWA), http://www.amwa.org,  
believes that these important contributions deserve recognition. 
3. Readers benefit from knowing about the involvement of professional writers and
editors.
Disclosing the editorial contribution and the source of funding of the writer and 
editor allows the reader to make informed judgments about the objectivity of the 
article.  
Note that the AMWA position statement recommends acknowledgment of 
pertinent professional or financial relationships as well as acknowledgment of the 
contributions of writers and editors.  
It also recommends that the person being acknowledged be given the opportunity 
to grant or refuse permission for the acknowledgment.  
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References:  
1. International Committee of Medical Journal Editors. Uniform requirements for
manuscripts submitted to biomedical journals. Ann Intern Med 1997;126:36-47.
Manuscript Guidelines  
• MS Word document (.doc) is required for all submissions.
• All figures must be uploaded separately as Image Files in Tagged Image File
Format (.tiff), Encapsulated Postscript (.eps) or PowerPoint (.ppt) with embedded
fonts.
• All submissions must be double-spaced, 1 inch margin, twelve-point font size in
Arial, Helvetica, Times New Roman and Symbol font (for non-text characters).
• All submissions must be page numbered.
• Do not use headers or footers.
• Use standard abbreviations and define all nonstandard abbreviations.
• All submissions require a title page.
• SI units must be used throughout your submission. Conventional units may only
be added as additional information in parentheses after the SI units. SI units are
available at Bureau International des Poids et Mesures.
• Supplemental Data are accepted for online publication only and is limited by
submission types (See Types of Submissions for details).
• Follow the guidelines for length restrictions, abstract, reference, table and figure,
and supplemental data limits as outlined in the chart below:
Un
ive
rsi
ty 
Of
 C
ap
e T
ow
n 
 114 
 
Type of Submission 
Word 
Limit* 
Structured** 
(S) or 
Unstructured 
(U) 
Abstract:Word 
Limit 
Maximum 
Number of 
References 
Total Number 
of 
Tables/Figures 
Supplemental 
Data 
Permitted 
Article 3,500 S: 250 40 6 Yes 
Bookshelf 500 
Non 
Applicable 
5 1 No 
Brief 
Communication 
1,500 S: 250 20 1 each*** Yes 
Citation Classics 700 
Non 
Applicable 
6 
Non 
Applicable 
No 
Clinical Case 
Studies 
(Case description) 
w/ 3-5 questions 
and up to 5 points 
to remember 
1,000 
(500) 
Non 
Applicable 
10 2 No 
Commentary 300 Non Non Non No 
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Applicable Applicable Applicable 
Editorial 1,500 
Non 
Applicable 
15 
Non 
Applicable 
No 
Letter to the Editor 
/ Reply 
750 
Non 
Applicable 
5 1*** No 
Mini-Review 3,500 S: 250 40 4 Yes 
Obituary 600 
Non 
Applicable 
Non 
Applicable 
1 No 
Opinion 1,500 
Non 
Applicable 
15 1 No 
Perspective 1,500 
Non 
Applicable 
5 1 No 
Point/Counterpoint 1,500 
Non 
Applicable 
15 1 No 
Reflection 2,000 
Non 
Applicable 
20 1 No 
Review 5,000 S: 250 75 6 Yes 
Special Report 5,000 S or U: 250 40 4 Yes 
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*Word limit consists of the body of the manuscript only; it does not encompass the title
page, abstract, acknowledgments, references, tables, figure legends, figures, or Clinical 
Case descriptions, questions, and points to remember. 
**Structured abstracts contain the headings (1) Background, (2) Methods, (3) Results, (4) 
Conclusions for all applicable article types except for Reviews and Mini-Reviews. 
Abstracts for Reviews and Mini-Reviews contain the headings (1) Background, (2) 
Content, (3) Summary. 
***If a figure accompanies the paper, the image should not be multipart (i.e., Fig. 1A. 
1B, 1C, Part 1, Part 2).  
Journal Categories  
Articles are grouped in the journal according to subject. Upon submission, authors are 
required to select the journal category that best describes their manuscript from the list 
indicated below:  
• Molecular Diagnostics and Genetics (MDG)
• Evidence-Based Laboratory Medicine and Test Utilization (TUO)
• Hemostasis and Thrombosis (HAT)
• Proteomics and Protein Markers (PPM)
• Cancer Diagnostics
• Lipids, Lipoproteins, and Cardiovascular Risk Factors (LLP)
• Drug Monitoring and Toxicology (DMT)
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• Hematology (HEM)
• Endocrinology and Metabolism (END)
• Point-of-Care Testing
• Automation and Analytical Techniques (AAT)
• Informatics and Statistics
• Laboratory Management (LMA)
• General Clinical Chemistry (GCC)
• Animal Clinical Chemistry (ANI)
• Clinical Immunology (CLI)
• Pediatric Clinical Chemistry (PED)
• Nutrition (NUT)
• Infectious Disease
• Other Areas of Clinical Chemistry (OTH)
Title page  
The first page of the manuscript should include the following information: (1) full title of 
submission, which should include only generic, not trade, names when describing a test, 
assay, etc.; (2) running head of fewer than 65 characters (including spaces); (3) list of all 
authors (first name, middle initial, last name in that order); (4) names of each author’s 
institution and an indication of each author’s affiliation; (5) name, address, telephone and 
fax number, and e-mail address of the corresponding author; (6) keywords; (7) list any 
previous presentation of the manuscript; (8) list abbreviations, in order cited; (9) list any 
“Human Genes" discussed in the paper. For each gene, indicate the gene symbol and 
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gene name approved by the HUGO Gene Nomenclature Committee. Include other 
name(s) that are used in the paper or are widely used in the literature for the gene.  
Abstract (Structured and Unstructured)  
Structured abstracts should be formatted to include separate headings of: (1) Background, 
(2) Methods, (3) Results, and (4) Conclusion. For Mini-Review and Review articles the
headings should be: (1) Background, (2) Content, and (3) Summary.  
Unstructured abstracts do not require separate headings.  
Bookshelf, Citation Classics, Clinical Case Study, Commentary, Editorial, Inspiring 
Minds, Letters to the Editor, Reply, Obituary, Opinion, Perspective, Point/Counterpoint 
submissions do not require an abstract.  
Abstracts must be uploaded to the abstract field of the Manuscript Metadata page online 
upon submission as well as the manuscript.  
Text  
The body of the manuscript should be written as concisely as possible and must not 
exceed the manuscript category word limits described herein. All pages must be double-
spaced and all lines numbered. The body of the paper should include: Introduction, 
Materials and Methods, Results and Discussion.  
• Introduction - why was the study undertaken?
• Materials and Methods - how was the study done?
• Results - what did the study find?
• Discussion - what might it mean, why does it matter, what next?
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Full corporate names of manufacturers of materials should be utilized and should include 
the city, state, and e-mail or website of the company.  
SI units are required; however, conventional units may follow in parenthesis.  
Use of human subjects requires a statement in the text indicating whether the procedures 
followed were approved by your institution's responsible committee or were in 
accordance with the current revision of the Helsinki Declaration and whether subjects 
gave informed consent.  
Disclosures/Conflict of Interest  
All authors are required to complete a full disclosure form upon submission. The 
disclosure form is electronic and completed during the submission process within the 
Bench>Press submission system. Complete disclosures must be submitted electronically, 
and should not be included within the submitted manuscript. Failure to adhere to this rule 
may result in a return of the submission to the author for correction. 
In order to complete disclosures, registration with Clinical Chemistry is required for all 
authors. 
In order to complete disclosures, register with Clinical Chemistry at 
Un
ive
rsi
ty 
Of
 C
ap
e T
ow
n 
 120 
http://submit.clinchem.org/cgi/registration using a valid e-mail address. Each author is 
required to be registered and must individually complete the disclosures. Please note that 
the e-mail address provided by the corresponding author at submission and registered 
authors’ email must match.  
 
Each author is expected to disclose any relevant financial relationships held personally or 
by a spouse/partner within the last 24 months. Any companies or proprietary entities 
producing scientific services, which have an investment, licensing, or other commercial 
interest in the subject matter under consideration in the submitted manuscript, must be 
disclosed.  
 
Such information is held in confidence while the manuscript is under review and does not 
influence the editorial decision on reports of research; upon acceptance, relevant 
information is added to the manuscript for publication.  
 
Authors of editorials are expected to be free of significant financial associations with 
companies that may be affected by topics discussed in the manuscript, and must also 
complete a full disclosure at the time of submission.  
 
The American Medical Writers Association (AMWA) recognizes the valuable 
contributions of biomedical communicators to the publication team. Biomedical 
communicators who contribute substantially to the writing or editing of a manuscript 
should be acknowledged with their permission and with disclosure of any pertinent 
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professional or financial relationships. In all aspects of the publication process, 
biomedical communicators should adhere to the AMWA code of ethics at 
http://www.amwa.org/default.asp? 
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Acknowledgments are limited to 60 words and should follow the main text of the 
manuscript directly above the reference section in a separate paragraph heading labeled 
“Acknowledgments.” They should not appear as footnotes.  
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References should appear in a separate section directly following the body of the 
manuscript. The section must be labeled “References” with no additional punctuation.  
• Italics or boldface type is prohibited in the referenced citations.  
• List and number the references in the order that they appear in the text.  
• Do not use the MS Word document (.doc) numbering tool. Number each 
reference manually with the numeral, a period, followed by a space.  
• For articles with more than seven authors, list the first six authors followed by "et 
al." For seven or fewer, list all authors.  
• Authors’ names are inverted (last name, first/second initial). Do not add periods 
or commas within an individual author name; however, separate author names 
with a comma and end the author list with a period (Smith J, Doe JJ, Adams B.).  
• Capitalize only the first word of the title or subtitle, and any proper names that are 
part of the title. The title should end with a period.  
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• The Journal names should be abbreviated as indicated at PubMed. For a list of
journal abbreviations, please visit: Link Out Journals.
• Do not add a period after the journal abbreviation, but continue with a space
followed by the year.
• The year should be followed by a semicolon and then the volume number which
is followed by a colon and then the page numbers; delete redundant numbers, for
example 1998;12:231-45.
• Do not include the months in parentheses, this information is not needed.
• Use inclusive page numbers for articles and book chapters.
Abstract and supplement numbers should be provided, if applicable. Citations of 
unpublished abstract books, manuscripts in preparation or under review, personal 
communications, and manufacturers’ information should only be cited in the text and 
should not appear in the reference list. Personal communications should also be listed 
parenthetically and should contain the first initial and last name of the contact as well as 
the month and year of the communication. Published manuscripts and manuscripts that 
have been accepted and are pending publication should be cited in the reference list.  
In press references cited in the reference list must be accompanied by a copy of the cited 
manuscript and a letter of acceptance, or a complete author proof from the publisher. 
These resources should be uploaded as supplemental data along with the manuscript and 
other print materials.  
The submission system will extract the references from the submitted MS Word 
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document (.doc) to display in a hyperlinked HTML format as an aid for reviewers and 
editors. This linking option allows for the checking of the correct formatting and the 
accuracy of the citations.  
 
Authors must check the linking of their references to PubMed during the “Ready for You 
to Proof” stage of submission. Correct linking of the references depends on strict 
adherence to Journal style as indicated.  
Reference Style  
• Journal article with seven or fewer authors:  
1. Vermeersch P, Mariën G, Bossuyt X. A case of pseudoparaproteinemia on 
capillary zone electrophoresis caused by geloplasma. Clin Chem 2006;52:2309-
11.  
• Journal article with more than seven authors:  
2. Fiechtner M, Ramp J, England B, Knudson MA, Little RR, England JD, et al. 
Affinity binding assay of glycohemoglobin by two-dimensional centrifugation 
referenced to hemoglobin Alc. Clin Chem 1992;38:2372–9.  
• Abstract:  
3. Hortin GL, King C, Kopp J. Quantification of rhesus monkey albumin with 
assays for human microalbumin [Abstract]. Clin Chem 2000;46:A140-1.  
• Editorial:  
4. Demers LM. New biochemical marker for bone disease: is it a breakthrough? 
[Editorial]. Clin Chem 1992;38:2169–70.  
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• Letter to the Editor:  
5. Davey L, Naidoo L. Urinary screen for acetaminophen (paracetamol) in the 
presence of N-acetylcysteine [Letter]. Clin Chem 1993;39:2348–9.  
• Book Chapter:  
6. Rifai N, Warnick GR. Lipids, lipoproteins, apolipoproteins, and other 
cardiovascular risk factors. In: Burtis CA, Ashwood ER, Bruns DE, eds. Tietz 
textbook of clinical chemistry and molecular diagnostics. 4th Ed. St. Louis: 
Elsevier Saunders 2006:903-81.  
• Thesis:  
7. Haughton MA. Immunonephelometric measurement of vitamin D binding 
protein [MAppSci thesis]. Sydney, Australia: University of Technology, 
1989:87pp.  
• Books and Monographs (serial volumes should be treated as journals):  
8. Harrell FE Jr. Regression modeling strategies. New York: Springer; 2001. 
9. Bailar JC III, Mosteller F, eds. Medical uses of statistics, 2nd Ed. Boston: 
NEJM Books; 1992:449pp.  
• Publish-Ahead of Print:  
10. Milbury CA, Li J, Makrigiorgos GM. PCR-based methods for the enrichment 
of minority alleles and mutations. [Epub ahead of print] Clin Chem February 6, 
2009 as doi:10.1373/clinchem.2008.113035.  
• Supplement:  
11. Castelli WP. Lipids, risk factors and ischaemic heart disease. Atherosclerosis 
1996;124 Suppl:S1-9.  
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• Internet Source:
12. American Association for Clinical Chemistry. AACC continuing education.
http://www.aacc.org/services/default.stm (Accessed November 1998).  
Tables  
Tables are considered text. They should appear embedded as part of the submission 
directly following the reference section. Each table should appear on an individual page. 
Manuscripts will be returned to authors if the tables are uploaded as separate files.  
Each table should be clearly labeled and numbered consecutively with Arabic numerals 
(Table 1, Table 2, etc.). The abbreviations used must be defined. As with the text, SI units 
must be used; however, conventional units may be added in parentheses. Conversion 
factors may be added as footnotes. Indicate explanatory footnotes with superscript 
lowercase italic letters in alphabetical order.  
Tables should not include parts. Tables with parts (Table 1A, Table 1B, etc.) will be 
returned to authors for correction.  
Table captions should be limited to 60 words.  
Each column of an individual table must have a heading and be clearly defined. Indicate 
explanatory footnotes with superscript lowercase italic letters in alphabetical order.  
Color tables will be considered for publication. As in the case with color figures, the 
costs of publishing color illustrations will be borne by the author. Costs are $1500 for the 
first color table and $500 for each subsequent color table, or part thereof. Please note the 
author agreement to pay in the cover letter.  
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Large, complex, or tables that include graphic elements should be submitted as figures or 
as supplemental data for online publication only. The Editor may choose to make any 
table supplemental as he/she deems necessary.  
 
Figure Captions  
Figure captions and sub-captions must be listed together on an individual page directly 
following the tables or the references if submission does not include tables. Each figure 
requires a figure caption and should be clearly labeled (Figure 1, Figure 2, etc.). Multi-
panel figures; figures with parts (a, b, c, etc.), should be distinctively labeled (Figure 1A, 
Figure 1B, Figure 2A, etc.).  
Figure captions should be limited to 60 words.  
If a figure has been published previously, acknowledge the original source in the figure 
caption and submit written permission from the copyright holder to reproduce the figure 
as supplemental data.  
 
Figures  
All figures must be uploaded separately as image files in Tagged Image File Format 
(.TIFF) or Encapsulated Postscript (.EPS). Microsoft Power Point (.PPT) is also 
acceptable; however, the graphics must contain embedded fonts with one image per slide, 
one slide per file. Each image should have a resolution of 600 dots-per-inch (dpi). More 
detailed specifications can be found on our print publication vendor’s page at CADMUS 
Digital Art Support.  
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The submission system is designed to retrieve the manuscript file and separate image 
file(s) and combine or merge the files into an individual Portable Document Format 
(.PDF) for reviewing purposes. It is the responsibility of the author to verify the quality 
of the image file(s) remains after the conversion to PDF. It may be necessary to alter the 
individual image file(s) to ensure the content is not lost or misconstrued in the merged 
PDF.  
Submissions will be returned to authors if the figures are embedded within the 
manuscript file and not uploaded separately, or the figures have become eligible in the 
merged PDF.  
Do not place unnecessary graphics, such as borders, in or around your figure. Pay 
particular attention to the quality of the lines, symbols, and patterns. Published figures are 
reduced to 1 column (85mm) or 2 columns (176 mm) in width. If, at that width, the figure 
symbols or lettering are not clear, you will need to increase the font size. Letters should 
be 8/10 points when reduced, subscripts no less than 6 point. Initial capitals and lower 
case letters and a medium (not bold) sans serif font is required. European PI, Helvetica, 
Mathematical PI, Times Roman, and Symbol fonts are Type 1 PostScript fonts supported 
by our printer for the creation of digital art figures.  
If publication quality electronic figure files cannot be provided, acceptable publication 
prints are:  
• Halftone: glossy prints  
• Line drawing: glossy prints, laser prints on coated (nonabsorbent) laser-printer 
paper, or drawings in black India ink on tracing paper.  
• Color: glossy prints, laser prints on coated (nonabsorbent) laser-printer paper  
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[Halftone: Image with blocks or portions that are gray opaque, such as a photograph; 
Line drawing: Image is in black and white only, such as a line graph; Color: Images 
where color is necessary to the meaning of the image]  
The x-axis and y-axis should be clearly labeled, and the units of measurements given. 
This includes using decimal points instead of commas, italicizing species or gene 
symbols, and using U.S. English.  
 
Color  
The costs of publishing color illustrations in print will be borne by the author. As with 
tables, costs are $1500 for the first figure and $500 for each subsequent figure, or parts of 
figures. Upon acceptance, authors will be billed for the color costs unless a request to 
print figures in black and white is received via cover letter or e-mail. Color versions of 
figures may be provided for publication in the on-line Journal at no extra charge. Please 
note your color preference and/or your agreement to pay for color printing in your cover 
letter.  
 
Supplemental Data  
Figures or tables too large for print, manuscript material that exceeds the limitation for 
the specific submission type, or appendices should be submitted for online publication 
only. These files should be marked and uploaded separately as supplemental files during 
submission, and should be referenced within the text as supplemental data (i.e., "See 
Supplemental Data Table 1", "See Supplemental Data Figure 1", etc.). Supplemental files 
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must be labeled consecutively (i.e., Supplemental Data Table 1, Supplemental Data Table 
2, Supplemental Data Figure 1, Supplemental Data Figure 2, etc.).  
Captions for the supplemental data should be uploaded as a separate supplemental file or 
embedded within the supplemental data/table/figure file. Do not include the supplemental 
captions in your manuscript file.  
Please be advised, supplemental data are permitted for Article, Brief Communication, 
Inspiring Minds, Mini-Review, Review, and Special Report submissions only. 
Manuscripts of all other types with supplemental data will be returned to authors.  
Supplemental data will be reviewed as part of the manuscript and will be evaluated for its 
importance and relevance; however, it should not appear in the “Peer-reviewed PDF” file 
created by the submission system.  
If accepted and posted online, the supplemental data will be referenced in the text of the 
print article directing readers to the URL of the Web site.  
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University of Cape Town 
Faculty of Health Sciences 
MMed/MPhil Part III (minor dissertation) 
Guidelines for candidates, supervisors and examiners 
 
Minimum Requirements for Dissertations for MMed and MPhil for Subspecialities 
Degrees 
 
Following extensive discussion with Heads of Divisions, Dr S Kalula and Prof S Kidson 
recommend the following minimum criteria for dissertations for MMed and MPhil 
(subspeciality) degrees: 
 
The MMed minor dissertation (or the MPhil dissertation in the case of sub-specialities) is 
one of three examination components of the MMed/MPhil degree. This minor 
dissertation carries one third of the weight of a full master’s dissertation in terms of its 
credit weighting. The dissertation must be a study containing the results of an analytical, 
quantitative, or epidemiological study carried out by the candidate (for certain 
disciplines, the candidate may chose instead to do a qualitative study, an audit cycle or a 
formal systemic review). A case report is not acceptable for the dissertation. 
The dissertation must be the result of independent work of the candidate conducted under 
the guidance and direction of a supervisor(s) and should demonstrate evidence of an 
ability to undertake research, to adequately interpret results and to comprehensively and 
critically review the relevant literature. Although the findings of the research need not 
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necessarily be original, they must be seen to advance scientific understanding. The topic 
and scope of research will depend on the particular disciplines and must be agreed upon 
in consultation with the supervisor(s). 
Research protocol 
Candidates intending to register for the MMed/MPhil Part III are required to submit a full 
research protocol for approval to their respective Departmental Research Committee 
(DRC). The candidate must also obtain FHS UCT Ethics approval prior to conducting 
their research. This full research protocol (together with a copy of the ethics approval 
letter) must be submitted to the postgraduate administration for approval by the Board of 
the Faculty of Health Sciences, prior to commencement of the research. For most 
disciplines, submission of the research protocol should be made no later than the end of 
year 2. The research protocol should outline the scope and content of the dissertation and 
must include the title of the proposed dissertation, name of the supervisor(s) and their 
brief curriculum vitae. 
Submission of dissertations 
On completion, the dissertation should be submitted to the Faculty Postgraduate Officer. 
The candidate should inform the Faculty Officer one month in advance of the intention to 
submit. 
Submission deadlines: 
1. March 15th for June graduation 
2. August 15th for December graduation 
Supervisors will be requested by the Faculty Postgraduate Officer to submit a letter 
supporting submission. This letter should be supplied by the primary supervisor. If this 
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supervisor is external, the internal supervisor must be kept informed at every stage of the 
process. Specific submission requirements may be set by individual disciplines.2 
Note on fees: To avoid attracting fees, dissertations need to be submitted before the 
beginning of the first quarter (first day of academic year), and before the start of the 
second semester (mid July) to qualify for a 50% fee rebate. 
Supervisors 
One cannot overemphasize the importance of identifying a dissertation supervisor as 
early as possible. The supervisor should be an individual who can relate to the 
candidate’s research project, be available for frequent and regular discussion and advice, 
and someone with whom the candidate can develop a good working relationship. Where 
specialised equipment and/or laboratory work is required for the study, the supervisor 
should assist in facilitating such access to such facilities. Supervisors may assist 
candidates in developing scientific communication skills but they are not required to do 
detailed editing or correction of spelling, grammar, or style. They may refer candidates to 
the UCT Writing Centre for this purpose. 
The primary supervisor may be based outside the candidate’s home department, faculty 
or university. In such a case, an internal (or secondary) supervisor will be required in 
addition to the primary supervisor, to serve as a guide and link to discipline-specific 
procedures. Primary supervisors retain responsibilities to the candidate and the university 
until the dissertation process is complete. 
Please note: in order to assist a candidate with a master’s research topic the supervisor 
needs to hold a master’s degree or higher, or have relevant research experience. If the 
primary supervisor does not hold a higher degree or equivalent (such as a Fellowship of 
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The College of Medicine of South Africa), then a secondary supervisor, who has a higher 
degree will need to be appointed in addition to the primary supervisor. 
Candidates are strongly encouraged to publish the study with the supervisor(s) as co-
author(s). This may require work beyond the graduation date. Such arrangements should 
be discussed and documented in advance. 
2 For Public Health Medicine and Occupational Medicine the dissertation must be 
submitted for examination at least 4 months prior to the deadline for registration for the 
examinations of the relevant College. This is in order to ensure that a final examination 
mark for the dissertation can be submitted by the candidate to the College of Medicine of 
South Africa (CMSA) at the time of registration as required by CMSA examination 
regulations. 
The dissertation 
Submission of the dissertation should satisfy the following criteria: 
1. The title page should contain the candidate’s name, dissertation title and the name of 
the university. 
It must also state the degree, e.g. Master of Medicine (MMed) in Public Health Medicine, 
Occupational Medicine, Family Medicine, Surgery, etc. The title page should also 
include a statement to the effect that the research report is based on independent work 
performed by the candidate and that neither the whole work nor any part of it has been, is 
being, or is to be submitted for another degree to any other university. It must also state 
that this work has not been published prior to registration for the abovementioned 
degree. 
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2. The body of the dissertation, which must be structured in 4 parts, should include the
following: 
Part A: The protocol (as approved by the Departmental Research Committee and Faculty 
Research Ethics Committee). The protocol should not exceed 4000 words. 
Part B: A structured literature review appropriate to the subject matter and methods of 
the dissertation. The literature review must, amongst other things, show that the student is 
sufficiently acquainted with the relevant literature and is able to perform a critical 
appraisal and, if appropriate for the topic, show a good understanding of evidence-based 
medicine. The review should be between 3 000 and 4 000 words. A suggested structure 
for the literature review is as follows: 
a) Objectives of literature review
b) Literature search strategy, including inclusion and exclusion criteria
c) Quality criteria - some leeway will be allowed here, as candidates will vary in their
ability to appraise studies. This will also vary with the nature of the dissertation. 
d) Summary or interpretation of literature
e) Identification of gaps or needs for further research
f) References (which will overlap with but will not be the same lists as in the journal
article and protocol) 
Part C: The results of the study must be presented in the form of a manuscript of an 
article for a named peer reviewed journal, meeting all the requirements set out in the 
“Instructions for Authors” of that journal, including the word count and referencing style. 
(Unless specially motivated, the journal chosen will need to allow for at least 3000 words 
excluding abstract, tables, figures and references). The “Instructions to Authors” of the 
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journal must be appended. The journal chosen for publication must be appropriate to the 
subject matter of the dissertation and accredited by the Department of Education or listed 
in the citation index of the Institute for Scientific Information (ISI). Important note: the 
candidate need not have submitted the article, not is the acceptance of the article and 
requirement for passing the degree. The norm of practice is to publish the study with the 
supervisor(s) as co-author(s) and candidates are strongly encouraged to submit their 
manuscript either before or after examination of the mini-dissertation. 
Part D: All supporting documents including: 
• Questionnaire/data capture instrument 
• Consent forms and any related participant information sheets 
• Technical appendices, including, if considered necessary, any additional tables not 
included in the main manuscript for the examiner to have available. These should be 
accompanied by a brief narrative. 
• Official Ethics approval letter from the Faculty Research Ethics Committee 
3. The article does not have to be submitted to the journal in order to meet academic 
requirements. 
4. A candidate must submit 2 copies of the dissertation in temporary binding, and an 
electronic copy on compact disc in a universally readable format (e.g. pdf). 
Examiners 
The full dissertation will be submitted for examination through the Postgraduate office of 
our Faculty to two external examiners (nominated by the supervisors and HOD).Three 
examiners will be nominated, two of which are invited to examine, and one held as an 
alternate. All examiners must be external to UCT. These nominations are circulated to the 
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Faculty Dissertation Committee. It is the supervisor’s (or co-supervisor’s) responsibility 
to submit names of potential examiners to the Faculty Officer when the candidate is ready 
to submit. The examiners will be well briefed regarding the specific requirements and 
criteria for submission and examination of the mini-dissertation. Such criteria will clearly 
explain the difference between the mini dissertation and a Master’s degree by dissertation 
alone. Details required for each examiner are: academic qualifications, postal and/or 
physical address, telephone and fax numbers and e-mail address, and one paragraph 
description of their standing in the relevant field (drawn from their CV if need be.) 
The candidate may not be informed of the identity of the examiners. After the outcome of 
the mini dissertation has been finalized, the examiners’ identities are made known if the 
examiners have indicated that they do not object to this. 
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